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Abstract 
Breast cancer is a malignancy of the epithelial cells comprising the mammary 
gland. As the ER is necessary for the growth of approximately 70% of breast cancers, 
pharmaceutical efforts have focused on uncovering modulators of the ERα such as anti-
estrogens and Selective Oestrogen Receptor Modulator (SERMs). SERMs differ from 
pure ER antagonists in their capacity to display tissue-selective and C promoter 
dependent agonist-antagonist activities. Tamoxifen (TAM) is a SERM that is used in the 
treatment of hormonally responsive breast cancer. TAM is the most commonly used 
treatment for patients with ERα positive breast cancer. 
In this study we examined the role of Oestrogen Receptor (ER) signaling in the 
regulation of tissue Transglutaminase 2 gene (TGM2). TGM2 encodes tissue 
Transglutaminase (TG2), a multifunctional enzyme with many cellular functions, such 
as matrix remodelling, stabilization of apoptotic cells and cell adhesion and migration 
which are thought to be implicated in inhibition of tumour growth and prevention of 
metastasis. Ligand activated ER has been shown to induce the transcription of the 
TGM2.  
Our results show mRNA expression of TGM2 by E2/ER in breast cancer cells is 
maintained in the presence of TAM but not the SERM Raloxifene. As we would expect 
this gene to be inhibited by TAM, this reveals an added layer of complexity to the 
pharmacology of TAM. To investigate this finding further we studied the effects of 
compounds which are structurally related to TAM, and found that compounds such as 
Endoxifen and 4-Hydroxytamoxifen have similar effects to TAM. To analyse the 
sequence requirements for ER induced activation of TGM2 transcription we cloned the 
5‟ regulatory region into a luciferase vector. Further study is required in this area to 
better understand the significance of TGM2 expression in breast cancer cells. 
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1 Introduction  
1.1 General Principles of Cell Signalling 
Multicellular organisms require elaborate mechanisms of communication 
whereby signals from one cell or group of cells influence the behaviour or function of 
another group of cells. This can involve direct cell-cell contact in which the signalling 
molecule present on the surface of a cell can directly contact a specific protein called a 
receptor on the surface on a target cell, initiating a cascade of events that alters the 
function of the target cell (Paracrine). The second mechanism of intercellular signalling 
involves secretion of a signalling molecule by a cell and the binding of the molecule to 
a receptor located either on the plasma membrane or intracellularly in the target cell 
(Endocrine) [1]. 
 Signaling molecules may act locally on the same cell (autocrine signalling) or 
on neighbouring cells (paracrine signalling) or at a distance as with endocrine 
signalling. Because secreted signalling molecules must travel in a hydrophilic 
extracellular environment, many signalling molecules are hydrophilic and unable to 
cross the plasma membrane. These molecules therefore bind to cell surface receptors 
and transmit signals intracellularly. Hydrophilic signalling molecules include proteins, 
peptides, amino acids, nucleotides, and certain dissolved gases including nitric oxide 
and carbon monoxide. Alternatively, lipophilic signalling molecules, including fatty 
acids, steroid hormones, vitamins D3, and retinoids, can diffuse across the plasma 
membrane lipid bilayer and bind to intracellular receptors found within the cytosol or 
the nucleus.  Because these signalling molecules are lipophilic, they travel through the 
extracellular milieu bound to carrier proteins. Within the target cell lipophilic molecules 
bind to intracellular receptors called nuclear receptors. 
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The nuclear receptor superfamily constitutes a family of intracellular receptors 
that effect transcriptional programs that play roles in a number of biological processes 
by responding to hormonal and metabolic signals.  
1.2 Nuclear receptor signalling 
1.2.1 The Nuclear Receptor Superfamily 
 In humans, the nuclear receptor superfamily consists of 49 different receptors 
(Figure 1.1). Many nuclear receptors are ligand-activated transcription factors that are 
expressed in a cell-restricted manner. Nuclear receptors (NR) can bind a host of 
endogenous ligands including steroid hormones, fatty acids, vitamin D3, xenobiotics, 
cholesterols, and bile acids, some NRs are orphan receptors whose endogenous ligand 
has not been identified.  
 
Figure 1.1 Nuclear Receptor gene family 
AR ERRα LRH PPARα reverbα SF1 
CAR ERRβ LXRα PPARγ reverbβ SHP 
COUPα ERRγ LXRβ PPARδ RORα TIX 
COUPβ FXR MR PR RORβ TRα 
COUPγ GCNF1 NGF1-Bα PXR RORγ TRβ 
DAX GR NGF1-Bβ RARα RXRα TR2α 
ERα HNF4α NGF1-Bγ RARβ RXRβ TR2β 
ERβ HNF4γ PNR RARγ RXRγ VDR 
Adapted with permission from Prof. D McDonnell, Department of Pharmacology and 
Cancer Biology, Duke University, NC. 
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Nuclear receptors share a common modular structure that includes 5-6 conserved 
domains, A through F (Figure 1.2) [2].  The A/B domain of the receptor is located at the 
N-terminus of the protein, and it contains a ligand-independent activation function 1 
(AF-1) domain.  This domain can activate transcription in an autonomous manner.  The 
A/B domain is the most variable of the domains and its length varies widely between 23 
amino acids for the vitamin D3 receptor (VDR) to over 550 amino acids for the 
androgen, mineralocorticoid, and glucocorticoid receptors [3].  The C domain of the 
receptor constitutes the DNA Binding Domain (DBD) of the receptor.  This domain 
confers upon the receptor sequence-specific DNA recognition through two zinc finger 
motifs.  The D domain of the receptor is a hinge region between the highly structured 
domains that precede and follow it.  This domain contains a nuclear localization 
sequence, which may play a role in the dynamic nuclear-cytoplasmic shuttling of 
nuclear receptors that occurs in response to ligand binding [4].  The E domain of the 
receptor is the Ligand Binding Domain (LBD), which is involved in ligand-binding and 
dimerisation.  The LBD also contains an activation domain called activation function 2 
(AF-2), which is a region of the protein involved in recruiting coactivator molecules 
that are essential for ligand-dependent transcriptional activity [5]. Some receptors, 
including the peroxisome proliferator-activated receptor (PPAR) family possess an F 
domain at the very C-terminus [6].  This domain is evolutionarily not well-conserved, 
and the roles of the F domain are largely unknown. 
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Figure 1.2 Modular structure of nuclear receptors 
 
Reprinted with permission from Prof. D McDonnell, Department of Pharmacology and 
Cancer Biology, Duke University, NC. 
 
1.2.2 General Mechanisms of Nuclear Receptor Signalling 
In an unliganded-state, nuclear receptors can be localised to either the cytoplasm 
or nucleus.  Upon ligand binding, nuclear receptors dissociate from any associated heat 
shock chaperone proteins to which they are bound, translocate into the nucleus, and 
homo- or heterodimerise on specific DNA nuclear receptor response elements (NRREs) 
within the promoters of target genes (Figure 1.3). The DNA binding domain, located in 
the centre of the protein, contains nine cysteine residues, eight of which can chelate two 
zinc molecules, forming two zinc fingers that bind to two adjacent major grooves in the 
DNA[7].  Nuclear receptors recognize variations of the hexameric motif 5‟-PuGGTCA 
(Pu = A or G) [3].  Some nuclear receptors, including the retinoid acid receptor (RAR), 
Vitamin D receptor (VDR), and thyroid receptor (TR) bind to direct repeats of the 
hexameric sequence separated by 1-5 nucleotides, termed DR1 through DR5 elements.  
The oestrogen receptor prefers a 5‟-PuGGTCA half site sequence, whereas GR prefers a 
5‟-PuG(G/A)ACA sequence.   
Nuclear receptors regulate gene transcription via several different mechanisms 
[8].  Through binding of various ligands, nuclear receptors can repress or activate 
transcription by recruiting corepressor and coactivator proteins, respectively [9].  
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Binding of agonist to the nuclear receptor alters the conformation of the AF-2 domain, 
facilitating the displacement of corepressors and the recruitment of coactivators.  Most 
coactivators contain a canonical LXXLL amino acid motif that interacts with the AF-2 
of the nuclear receptor.  Recruitment of coactivators is essential for nuclear receptor-
mediated gene transcription; their role is to facilitate transcription by remodelling the 
chromatin and recruiting RNA polymerase II and the general transcriptional machinery. 
Binding of antagonist to the nuclear receptor facilitates the recruitment of co-repressors; 
which leads to recruitment of histone deacetylases, condensation of chromatin and 
dampening of transcriptional activity.   
 
Figure 1.3 The mechanism of action of intracellular receptors  
 
Ligand passes through the cell membrane and binds steroid receptors in the cytoplasm 
or nucleus. Binding of ligand induces a conformational change in the receptor structure 
permitting dimerisation and binding to specific nuclear receptor responsive elements 
(NRRE) in the DNA structure. The recruitment of general transcription activators 
(GTA) to the complex allows for the induction of gene transcription and production of a 
protein. Adapted with permission from [10]. 
  
=Ligand 
Cell 
Membrane 
Nuclear 
Membrane NRRE 
Transcription 
mRNA 
Translation 
New Protein 
Binding Altered 
Cell 
Function 
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1.2.3 Oestrogen Signalling 
Oestrogen is probably the most widely studied of all hormones, the term 
„oestrogen‟ refers to a group of chemically similar hormones, estrone (E1), estradiol 
(E2), and estriol (E3) (Figure 1.4). These hormones are uniquely responsible for the 
growth and development of the female sexual characteristics.  Estradiol and estrone are 
produced primarily in the ovaries in pre-menopausal women, while estriol is produced 
by the placenta during pregnancy. Oestrogen acts on cells in a wide variety of tissues 
including breast, uterus, brain, bone, liver, and heart to modulate cell activity. For 
example, oestrogen controls growth of the uterine lining during the first part of the 
menstrual cycle, and cause changes in breast during adolescence and pregnancy and 
regulates various other metabolic processes such as bone growth and cholesterol levels.  
1.2.4 Oestrogens 
Figure 1.4: The structures of the three oestrogens 
 
 
The three oestrogens, estrone (E1), estradiol (E2), and estriol (E3), are the most 
abundant and well-studied endogenous agonists for ER (Figure 1.4). The biosynthesis of 
oestrogen in the ovary is initiated in the early follicular stage of the reproductive cycle 
in response to follicle stimulating hormone (FSH), a pituitary hormone whose receptor 
is expressed in ovarian granulosa cells.  Upon receipt of the signal, cholesterol is 
mobilized from the outer mitochondrial membrane (OMM) to the inner mitochondrial 
membrane (IMM) by steroid acute regulatory protein (STAR).  At the IMM, cholesterol 
is converted to pregnenolone by the action of the cholesterol side chain cleavage 
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enzyme cytochrome P450 (CYP) 11A1 (CYP11A1).  From there, pregnenolone is 
metabolized by numerous CYPs, hydroxysteroid dehydrogenases (HSDs), and 
hydroxysteroid reductases to produce oestrogens, as well as other steroid hormones 
(Figure 1.5).  
 
Figure 1.5: Steroidogenesis 
 
A diagram of the reactions in the steroidogenic pathway that contribute to the synthesis 
of endogenous oestrogens, highlighting the enzymes that catalyze these reactions. 
 
Oestrogens can be metabolized through several mechanisms, including oxidation 
by CYPs, sulfation by sulfotransferases, glucuronidation by uridine diphosphate-
glucuronosyltransferases (UGT), and O-methylation by catchol O-methyltransferases 
(COMT) (Figure 1.6) [11].  The primary site of E2 metabolism is the liver, where 
CYP1A2, CYP3A4, and CYP1B1 mediate 2 – and 4-hydroxylation of E2.  Outside the 
liver (in the breast, uterus, placenta, brain, and pituitary) CYP1A1, and to some extent 
CYP3A4, converts E2 to the 2-hydroxylated form.  COMT rapidly methylates 2-
hydroxy-E2 to avoid free radical formation and is thus considered to be anti-
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tumourigenic.  In the breast and uterus, CYP1B1 actively produces high levels of 4-
hydroxy-E2. Unfortunately, 4-hydroxy-E2 is rapidly converted between semiquinone 
and quinone forms, which generate free radicals that cause DNA damage, and thus 
CYP1B1 metabolism of E2 is considered genotoxic.  There is evidence to suggest that 
E2 can control the expression of its metabolic enzymes, although the data is not clear 
[11].  Oestrogens function through ER to control particular biological processes, as 
discussed below. 
 
Figure 1.6 Oestradiol Metabolism 
 
The creation and metabolism of E2 is catalyzed by many members of the CYP family.  
E2 metabolites fall into two main categories, those that are genotoxic and those that 
may inhibit tumourigenesis [11]. 
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1.2.5 The Oestrogen Receptor 
ER is a member of the nuclear receptor (NR) super-family of ligand-activated 
transcription factors.  There are two genetic subtypes of ER, ER and ER, which 
exhibit overlapping but distinct activities and expression patterns [12-15].  They share 
the same modular structure: an N-terminal A/B domain, the C domain containing the 
zinc-finger DNA binding domain (DBD), a hinge region (D domain), the E domain 
which houses the ligand binding domain (LBD), and the C-terminal F domain (Figure 
1.7).  Given their high degree of homology in the LBD and DBD, it is not surprising 
that ER and ER regulate mostly identical DNA response elements and bind many of 
the same endogenous and exogenous ligands [14, 16].  Tissue distribution patterns and 
knockout mouse models of ER indicate that ER and ER are not redundant, and 
instead suggest unique tissue-specific functions for each receptor subtype [12, 17].  
ER is more ubiquitously expressed throughout the body, whereas the pattern of ER is 
restricted to the testis, ovary and thymus [12].  Together, ER and ER control many 
important biological processes, including ovulation, mammary gland development, 
proper bone mineral density, cardiovascular function, aspects of mating behaviour, and 
the immune system [17]. 
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Figure 1.7 Schematic of ER structure 
 
Schematic illustration of ER modular structure, highlighting the amino acid similarity 
between ER and ER. Adapted with permission from [18]. 
 
Residing in either the cytoplasm or nucleus, signalling through ER is initiated by 
either ligand binding or by ligand-independent processes such as phosphorylation.  The 
transcriptional activity of ER is mediated by the activation functions (AFs), of which 
there are two in ER (AF-1 and AF-2) but only one in ER (AF-2).  AF-2 is located 
within the LBD and is primarily responsible for ligand-dependent activation of 
transcription, whereas AF-1 is thought to transduce ligand-independent transcriptional 
activation.  When both are present, as in ER, AF-1 and AF-2 can function 
synergistically or independently, depending on cell and promoter context, thus adding a 
layer of complexity [19].  The distinct biologies of ER versus ER may stem from the 
divergent A/B and F domains, particularly since no obvious AF -1 domain is found in 
ER. 
1.2.5.1 Activation of transcription 
To activate transcription, the general transcriptional machinery must be recruited 
to DNA.  Although it was once considered that ER directly interacted with this 
machinery, it is now apparent that the protein-protein interaction surfaces on ER recruit 
coregulatory proteins, such as coactivators and corepressors, which bridge this 
11 
 
interaction (Figure 1.8). Coregulatory proteins interact primarily with ER at the AF-2 
domain, where a hydrophobic pocket is formed predominantly by helix 12 (H12) 
(Figure 1.9) 
Figure 1.8 Diagram of ER agonist and antagonist activity 
 
The binding of agonist to the ER induces a conformational change in the receptor 
structure which facilitates dimerisation and recruitment of coactivators to the receptor 
complex. This allows for the activation of transcription of E2 regulated genes. The 
binding of agonist to the ER facilitates dimerisation and recruitment of corepressors 
which does not lead to gene transcription. Corepressor (CoR), coactivator (CoA). 
Adapted with permission from [20]. 
 
Figure 1.9 Structure of the nuclear receptor/coactivator complex 
 
The interaction of ER AF-1 and AF-2 with coactivator (CoA). Adapted with permission 
from [20]. 
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This pocket binds the hydrophobic sequence LxxLL found in coactivators. [21] 
Coactivators can promote transcription through several mechanisms: the acetylation of 
histones by steroid receptor coactivators (SRC) -1, -2, and -3, thyroid hormone receptor 
activating protein of 220kDa (TRAP220), and CREB-binding protein (CBP/p300); the 
methylation of histones by protein arginine methyltransferase 1 (PRMT1); RNA 
processing by RNA helicases such as p68; and the coupling of ER to degradation 
machinery through the ubiquitin ligases E6-associated protein and ribosome production 
factor 1. [22-23] The other class of coregulatory proteins, the corepressors, contain a 
similar domain, the CoRNR box motif, that binds to the hydrophobic pocket in ER [24].  
In general, corepressor proteins either recruit or exhibit intrinsic histone deacetylase 
activity, thereby actively repressing transcription (Figure 1.10).  
 
Figure 1.10 ER-associated cofactors 
 
Diagram showing coactivators (+), corepressors (-) and other associated proteins. 
Oestrogen receptor shape influences cofactor binding preferences [10]. Adapted with 
permission from [25]. 
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After binding to ligand, ER undergoes a conformational change that is critical in 
dictating the downstream biological response.  Previously, it was thought that there 
were only two conformations that ER could adopt; an active and an inactive one.  
However, the discovery that different ligands confer unique responses made this model 
unlikely.  Instead, it appears that each ligand induces a unique conformational change 
that allows for differential presentation of protein-protein interaction surfaces that are 
used to couple ER to other signalling pathways, therefore determining the cellular 
response to a particular ligand [26]. 
After binding to oestrogen and undergoing a conformational change, ER 
dimerises and binds to DNA within the regulatory regions of target genes [27].  Direct 
ER binding to DNA occurs at oestrogen response elements (EREs), whereas ER can 
also interact indirectly with DNA through binding to Fos and Jun at AP-1 (activator 
protein 1) elements [28] or to specificity protein 1 (Sp1) family members at GC-rich 
DNA regions [29].  The specific ERE sequences influence the affinity of ER binding by 
inducing a unique conformation in the ER structure which may contribute to the 
promoter specific activities of the ER on different ERE-containing genes [30].  The 
canonical ERE was determined to have the consensus sequence 5‟-
GGTCAnnnTGACC-3’ [31-32]. The symmetry of the sequence facilitates the binding of 
ER as a homodimer [33]. However, only a handful of the most highly oestrogen-
responsive genes actually contain perfect consensus EREs. Many genes have been 
found to contain sequences that appear to be EREs, but most of these vary from the 
consensus by one or more nucleotides. Studies of ER binding showed that one or more 
changes from the consensus sequence resulted in lower ER-ERE affinity and that 
sequences immediately flanking the ERE impact ER-ERE binding [34]. One study has 
performed a genome-wide analysis of oestrogen receptor binding sites, identifying a set 
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of 3665 unique ER binding sites. This study has shown that the percentage of 
upregulated genes in breast tumours with an ER binding site within 100kb is 56 - 59%. 
Also almost one-third of early-oestrogen upregulated genes have ER binding sites 
within 50kb of the transcription start site [35], while there at least 236 genes with a 
consensus ERE within -10 to +5 kb of the 5‟ end [36].  
Besides binding ERE sequences on the gene promoter, ERα or ERβ can activate 
transcription through different types of DNA enhancer elements such as AP-1 sites. 
This requires ligand-bound ER and the AP-1 transcription factors Fos and Jun. ERα or 
ERβ both have different transactivation behaviour at Ap-1 sites.  
After initiating transcription, ER undergoes ligand-mediated degradation 
through the 26S proteosome.  The activity of particular coactivators, such as AIB1 
(amplified in breast cancer 1), has been shown to be necessary for ER degradation 
under certain contexts [37], therefore bringing forth the hypothesis that DNA-bound 
ER recruits the proteins that target it for destruction.  The complete identity of these 
proteins, and whether they interact with ER in the same way as coactivators, has yet to 
be fully elucidated.  Further, ER does not undergo ligand-dependent degradation, 
despite efficient transcription, suggesting perhaps that another surface outside the 
coactivator binding groove may be responsible for recruitment of the degradation 
machinery. 
Besides its well-studied role in modulating transcription of target genes, ER may 
also regulate other biological processes in both the nuclear and cytoplasmic 
compartments through both ligand-dependent and –independent mechanisms. These 
include association with the phosphotidylinositol-3-kinase (PI3K), insulin-like growth 
factor 1 (IGF-1), and extracellular signal-regulated kinase/mitogen-activated protein 
kinase (ERK/MAPK) pathways. IGF-1, like E2 is a potent mitogen which is involved in 
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a large array of processes that control proliferation and differentiation in mammalian 
cells. One study has shown that E2 activates IGF-1 receptor and ERK1/2 via ERα 
leading to activation of the IGF-1 signalling cascade [38-40]. Activation of IGF-1 
receptor leads to the selective recruitment of downstream signaling molecules and 
results in activation of the Ras/Raf/MAPK signaling cascade. Phosphorylation of ERα 
at serine 118 is required for full action of AF-1, as ER activation by growth factors 
involves the MAPK pathway; this is another potential interaction site of the two 
pathways [41]. This cross-talk between IGF-1 receptor and ER signalling pathways 
results in synergistic growth stimulation. 
It has also been established that oestrogens induce rapid increases in cAMP as 
well as activation of phospholipase C [42]. The time course of these acute events 
supports the hypothesis that they do not involve the „classical‟ gene activation action of 
oestrogens. Through interaction with these pathways, ER activity can be regulated by 
direct phosphorylation or by phosphorylation of its coactivator and corepressor proteins. 
The exact role of these phosphorylation events, and other potential post-
translational modifications, on the signalling competency of ER and its coactivators 
remains to be fully elucidated. These pathways may play a pivotal role in oestrogen-
independent breast cancer cell growth and tamoxifen-resistance.  
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1.3 Breast Cancer 
1.3.1 General information 
In 2007 there were 2463 new cases of breast cancer in Ireland, the number of 
new cases has been rising steadily each year (+2.4%). However mortality rates have 
dropped by about 2% per annum (1994-2004), likely due to increased early detection, 
better therapeutics, and successful prevention strategies. Breast cancer is the most 
common cause of cancer death in women, at over 660 deaths per year (National Cancer 
Registry). 
Breast cancer is a malignancy of the epithelial cells comprising the mammary 
gland.  Many risk factors have been identified for breast cancer, including lifetime 
exposure to endogenous hormones, obesity, increased age, family history, and alcohol 
consumption.  The primary treatments for breast cancer are surgery, radiation therapy, 
and systemic chemical therapy, which include chemotherapeutics and 
endocrine/hormone therapy.  
1.3.2 The role of oestrogen and ER in breast cancer 
Oestrogens and ER have been implicated in many cancers, but none so clearly as 
breast cancer.  In 1896 it was first suggested that ovariectomy induced regression of 
metastatic breast cancer [43], and by 1900 it became clear that this surgery had a one-
third response rate in metastatic breast cancer [44].  The discovery of oestrogen in 
ovarian follicular fluid set the stage for the development of compounds that either 
mimic or inhibit classic oestrogenic responses [45].  Breast cancer cells may be either 
positive or negative for the ER; most ER positive breast cancer cells require the ER for 
growth and survival. ER positive breast cancers exhibit stronger clinical responses to 
hormonal treatment and have a more differentiated morphologic appearance [46-47].  
17 
 
In mammary epithelial cells, E2 signalling through ER promotes cellular 
proliferation, which when unchecked can lead to pathologic disease. Even after 
menopause, when systemic E2 production is largely decreased, adipose tissues continue 
to make E2 and many breast tumours acquire the ability to locally produce E2 through 
expression of the aromatase enzyme (CYP19) [48-49].  In addition to promoting cell 
proliferation, E2/ER engages the ERK/MAPK and PI3K signalling pathways to 
increase cell proliferation and survival. As discussed earlier, some metabolites of E2 are 
DNA damaging agents that may increase DNA mutagenesis, leading to increased 
probability of cell transformation [49-50]. 
1.3.3 Breast Cancer pharmacology 
Given the implication of E2/ER signalling in the aetiology of breast cancer, 
pharmaceutical efforts have uncovered many natural and synthetic modulators of ER 
activity and E2 synthesis with a wide range of activities.  The Selective ER Modulators 
(SERMs) are characterized by three important qualities: they bind competitively to ER, 
they induce a unique conformational change in ER that facilitates differential cofactor 
interactions, and they exhibit promoter- and tissue-specific activity (Figure 1.10). 
SERMs allow the ER to adopt a structure which is intermediate between that observed 
following the binding of agonist or antagonist, which may or may not lead to gene 
transcription.  
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Figure 1.11 ER activation complex showing the selective nature of Tamoxifen in 
different cells. 
 
 
 
 
The activities of AF-1 and AF-2 are manifested in a cell-specific manner. (A) In some 
cells the interaction of both ER-AF domains with a cellular cofactor is required for 
transcriptional activity. In these cell contexts, estradiol (E2), but not tamoxifen, 
functions as an agonist. (B) In other cell contexts, ER-AF-1 alone is required for ER 
transcriptional activity. Therefore Tam is an AF-1 agonist. Reprinted with permission 
from [51]. 
A 
B 
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Tamoxifen (TAM) and raloxifene (RAL) are SERMs that have clinical utility in 
breast cancer (Figure 1.12), and the tissue-specific activity profiles of these compounds 
as compared to E2 are shown in Table 1.1. In the context of the breast, both TAM and 
RAL are considered ER antagonists based on their ability to block coactivator 
recruitment to ER and thus transcriptional activation, yet they have different biological 
consequences as assessed by their individual abilities to decrease the risk for either 
invasive or non-invasive breast cancer. Whereas TAM decreases the risk for both 
invasive and non-invasive breast cancer, RAL only decreases the risk for invasive breast 
cancer, suggesting perhaps that differences exist in their mechanism of action in the 
breast [52]. Raloxifene has been shown to decrease the risk of invasive breast cancer by 
76% during 3 years of treatment. This was attributable to a 90% reduction in the risk of 
ER-positive breast cancer, while there was no apparent decrease in the risk of ER-
negative breast cancer [53]. A distinction between TAM and RAL is highlighted in the 
uterus, wherein TAM is an ER agonist and thereby increases the risk for 
endometrial/uterine cancer and endometriosis, but RAL is an ER antagonist [54]. 
Therefore SERMs display tissue-selective pharmacology, acting as an agonist in some 
tissues and antagonists in other tissues. Also E2, TAM, or ICI (ICI 182,780) bound ERα 
will all activate transcription through AP-1 whereas only TAM or ICI bound ERβ 
activates transcription through Ap-1 [55]. This reveals a potential control mechanism 
for transcriptional regulation of E2-responsive genes and also adds a layer of 
complexity to the differential pharmacology of TAM 
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Figure 1.12 Structures of Tamoxifen and Raloxifene 
 
Reprinted with permission from [51]. 
 
Table 1.1: The relative agonist activities of SERMs 
  
The relative activities of E2, Tamoxifen and Raloxifene in various cell types. [52-53] 
 
 
The active form of Tamoxifen, 4-Hydroxytamoxifen (4OHT), has been shown to 
be exhibit 30 to 100-fold higher potent anti-oestrogenic activity than that of Tamoxifen 
[56]. For this reason Tamoxifen is often referred to as a pro-drug that requires 
conversion to its hydroxylated metabolite to exert its activity. The secondary metabolite 
of 4OHT, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen), is as potent as 4OHT with 
respect to ER binding and inhibition of E2 induced cell proliferation. Endoxifen is 
formed by the cytochrome P450 2D6 (CYP2D6) and has been shown to be present in a 
6 fold higher concentration than 4OHT in patients receiving Tamoxifen. Therefore this 
may suggest that Endoxifen could be a more important contributor to Tamoxifen 
activity than 4OHT [57]. 
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Bazedoxifene is a SERM which is currently under development by Wyeth 
Pharmaceuticals for the prevention and treatment of osteoporosis. Bazedoxifene is 
shown to transactivate the ER, and positively affect the skeletal and lipid profile without 
stimulating the uterine endometrium, causing breast cancer proliferation, or negatively 
impacting the central nervous system [58]. Lasofoxifene is a nonsteroidal SERM which 
is currently under development by Pfizer for the prevention and treatment of 
osteoporosis and vaginal atrophy. Lasofoxifene binds ERα and ERβ selectively (100 
fold selectivity against all other NRs) and with high affinity [59]. 
Another class of ER ligands that has been developed clinically is the selective 
ER down-regulators (SERDs), which include ICI and GW5638.  SERDs, similar to 
SERMs, bind competitively to ER, but have the additional activity of inducing rapid re-
compartmentalisation and degradation of ER protein. This activity contributes to the 
efficacy of SERDs such as ICI as a second-line therapy for patients who have failed at 
least one endocrine therapy, such as in Tamoxifen-resistant breast cancer. GW5638 has 
been shown to function as oestrogen in skeletal and cardiovascular systems while 
opposing the actions of oestrogen in the breast and uterus. Importantly, it also inhibits 
the growth of tumours that are resistant to (or stimulated by) Tamoxifen.  
Besides inhibiting ER signalling at the level of ligand binding, another way to 
impact ER signalling is to reduce the concentration of its agonist, E2.  As mentioned 
above, E2 synthesis from testosterone requires the aromatase enzyme, which also 
catalyzes the conversion of androstenedione to E1.  Thus, aromatase inhibitors (AIs), 
such as anastrozole, exemestane, and letrozole, have been developed [60].  However, 
only 40 – 50 % of patients respond to AIs, suggesting de novo or acquired resistance 
mechanisms of circumventing this particular block in E2 synthesis.  One hypothesis is 
that breast tissue expresses high levels of steroid-sulfatase expression, which converts 
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E1-3-sulfate into the un-sulfaconjugated form, whereby subsequent action of 17-HSD 
creates E2 [61].  Other rationales maintain that perhaps not all ER-positive breast 
cancers rely on E2 and may instead rely on other endogenous oestrogenic compounds 
[62], or that distinct molecules and signalling pathways, such as the epidermal growth 
factor receptor (EGFR)/MAPK pathway [63], compensate in the face of an AI to 
continue to induce cell proliferation and survival.   
The addition of targeted therapies to traditional chemotherapeutic regimens has 
provided significant benefit with relatively mild side effects. For example, treatment of 
early-stage ERα positive breast cancer with Tamoxifen, results in a 30% reduction in 
annual mortality. Use of an aromatase inhibitor, such as Letrazole, shows comparable 
benefit with an improved side effect profile; the most serious common side effect, 
cardiovascular events, occurs in less than 1% of patients. The success of anti-oestrogen 
therapies in the treatment of breast cancer highlights the importance of E2 and ER in 
the development and progression of this disease, but both de novo and acquired 
resistance suggest that there is still much to learn.  A more thorough understanding of 
the signalling pathways and how they interact and intersect will allow for the 
development of superior targeted therapies as well as better biomarkers that predict risks 
and likelihood of response to a given therapeutic. 
1.3.4 Breast cancer cell lines as in vitro models 
The study of breast cancer cell lines powerfully informs both our molecular 
understanding of this disease and the development of novel therapeutic agents. Current 
research aims to closely analyse tumour heterogeneity and tumour-stromal interactions 
in in vitro models of cancer. The majority of the breast cancer cell lines were derived 
from metastatic tumours as the highly malignant nature of these cells facilitates their 
long-term proliferation. Three cell lines that were developed in the 1970‟s (MCF-7, T-
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47D and MDA-MB-231) were used in the vast majority of published breast cancer 
studies. However there are some disadvantages in using cell lines as these are prone to 
genotypic and phenotypic drift during their continual culture. One study highlighted 
many discrepancies in MCF-7 cells obtained from different laboratories, demonstrating 
variations in cell growth rate, hormone receptor content, karyotype and clonogenicity 
[64]. Another pitfall of using these breast cancer cell lines is that most of these cells are 
derived from tumour metastasis rather than the primary legion. Thus research based on 
such cell lines will be biased towards more rapidly progressive types of breast cancer 
and to late stage disease rather than lower grade and earlier stage breast cancer. An 
alternative to using cell lines is to prepare primary cultures derived directly from a 
breast tumour which has the advantage of being able to compare the characteristics of 
the culture with those of the original tumour. However primary cultures have slow 
population doubling times and a finite lifespan also these cells may behave differently 
in culture compared to their response when they are part of a tissue/organ. Because of 
the ease of use of cell lines they remain the model of choice for breast cancer research, 
however it is important to understand their limitations and take these into consideration 
when designing experiments and interpreting results. 
The general attributes of breast cancer cell lines (such as ER positive or 
negative) necessarily informs the choice of a particular cell line in the experiment as 
well as the interpretation of experimental results [65]. MCF-7 cells are used in the 
majority of the experiments in this study as these cells express ERα but do not express 
ERβ. 
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1.4 Tissue Transglutaminase 
1.4.1 Physiological Functions 
 Tissue or type 2 transglutaminase (TG2,1 EC 2.3.2.13) is a ubiquitously 
expressed multifunctional enzyme belonging to the transglutaminase family which is 
coded by the TGM2 gene [66]. Tissue Transglutaminase protein (referred to as TG2) is 
a 687 amino acid protein and 77329 Da in size. Its primary function is catalyzing the 
Ca2+ -dependent acyl transfer reactions between carboxamide groups of glutamine 
residues and amino groups in lysine residues in peptides, forming cross-links in 
proteins. Transglutaminases are expressed in a variety of tissues and differ in their 
pattern of expression, substrate specificity and their physiological regulation. Some 
members of the transglutaminases such as Factor XIIIa, which is involved in blood 
clotting, are secreted from the cell and are involved in cross-linking of plasma proteins. 
Other transglutaminases, such as keratinocyte transglutaminases, are intracellular 
enzymes which play a major role in cross-linking proteins in the differentiation and 
cornification of skin cells [67]. Tissue transglutaminase (TG2) is an intracellular 
transglutaminase which may be secreted from the cell where it is involved in processing 
the matrix that occurs during osteogenesis, wound healing and other remodelling 
processes [68]. However the enzyme‟s method of secretion is not fully understood. Like 
Factor XIII and several other extracellular proteins, tissue transglutaminase does not 
contain a leader peptide or obvious secretory signal and it remains to be determined how 
the enzyme becomes deposited in the extracellular compartment. One study has shown 
that increased expression and activation of TG2 leads to increased externalisation of the 
protein, whereas inactive TG2 was not externalised. This study also showed that 
exposure of the active site is key in determining enzyme secretion [69].  
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Evidence also exists to show that TG2 has a role in apoptosis, where both high 
levels of the protein synthesis and enzymatic activity are observed. Activation of TG2 
crosslinking activity during both physiological and pathological apoptosis leads to 
assembly of an intracellular protein scaffold contributing to the stabilization of dying 
cells, before their clearance by phagocytosis. TG2 therefore stabilizes the integrity of 
the apoptotic cells, preventing the release of harmful intracellular components into the 
extracellular space. In non-apoptotic cells the binding of GTP prevents the activation of 
TG2, allowing the cell to survive in the presence of high TG2 protein levels [70]. 
During apoptosis the drop in intracellular GTP and an increase in Ca2+ lead to the 
activation of TG2. Cell surface-bound Tissue Transglutaminase is also thought to be 
involved in cell adhesion and cell migration processes by a mechanism independent of 
its cross linking activity [71]. 
1.4.2 Oestrogen Receptor control of TGM2 expression  
It has been previously shown that E2 activates the TGM2 gene in cells which 
contain either ERα or ERβ. This ER-induced activation is inhibited by ICI 182780 [72]. 
It is thought that the ER activates TGM2 through an ERE located in its promoter. The 
proximal TGM2 promoter contains an 8/10 match with the canonical ERE 
(GCGGTCAAGG CTACCTG) (Figure 1.13). 
As discussed earlier the ER may also mediate gene transcription from an AP1 
enhancer element that requires ligand and the AP1 transcription factors Fos and Jun for 
transcriptional activation. The TGM2 promoter contains a 6 out of 7 match to the 
canonical AP-1 site (TGAGCA) (Figure 1.13). 
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Figure 1.13 TGM2 5’ flanking region with putative ERE and AP-1 sites 
 
 
Diagram of TGM2 5‟ flanking region showing putative ER binding sites, CpG 
methylation site, translation start site and transcription start site. 
 
The proximal promoter of this gene includes two CpG-rich regions, well 
recognised sites of DNA methylation. These sites are concentrated in two clusters of 
CpG dinucleotides; one is located in the core promoter (nucleotides -205 to +75) 
(Figure 1.13) and the other is located approximately 1.3kb upstream. One study has 
shown that methylation of the proximal CpG region results in a marked decrease in 
transcriptional activity while demethylation increases transcription [73]. This study 
describes a mechanism for the negative regulatory control of TGM2 by DNA 
methylation. Release from the inhibition of this regulatory mechanism may play an 
important role in controlling the level of transglutaminase expression in a tissue-specific 
manner. 
1.4.3 Role of TG2 as a tumour suppressor 
The growth and development of new tissue in physiological and pathological 
conditions relies on the generation of new blood supply. The control of inappropriate 
angiogenesis in diseases such as cancer has been a keen area of research, leading to the 
development of novel anti-angiogenic agents. While some of the functions of TG2 
protein are similar to those required for angiogenesis, the role of TG2 in this process is 
poorly understood. It has been shown that TG2 is down-regulated in epithelial cells 
undergoing capillary angiogenesis; also TGM2 gene knock-out mice show no vascular 
abnormalities [74]. These findings fit in with the proposed role of TG2 in extracellular 
CpG Island 
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matrix stabilisation, since angiogenesis requires local destabilisation of the matrix. One 
study has shown that application of exogenous TG2 blocks angiogenesis in a dose-
dependent manner without causing cell death. The same study also shows that 
intratumour injections of TG2 inhibited tumour growth and increased survival in mice 
bearing carcinoma tumours. Also tumours grafted into TGM2 knockout mice (TGM2-/-) 
showed a significant increase in tumour growth compared to TGM2+/+ mice [75]. 
1.4.4 TG2 in chemotherapy resistant breast cancer 
Chemotherapeutic drugs such as Doxorubicin are used in the treatment of breast 
cancer. This drug is known to intercalate DNA thus preventing transcription; it also 
inhibits the topoisomerase type II enzyme stopping the process of replication. 
Resistance to chemotherapy is a major obstacle to successful treatment of breast cancer. 
Although chemotherapy drugs are outside the focus of this study, the implications of 
TG2 protein in drug resistance is relevant.  A direct link has been established between 
the development of drug resistance and metastatic phenotypes in breast cancer and 
increased expression of TG2. One study demonstrated that TG2 protein expression is 
up-regulated in drug-resistant and metastatic breast cancer cells, and it could serve as a 
prognostic marker for the development of these phenotypes [76]. 
As discussed earlier, many reports have supported the involvement of TG2 in 
apoptosis; its overexpression primed cells for apoptosis whereas its inhibition by 
antisense RNA rendered the cells resistant to induction of apoptosis [77]. Contrary to 
this, recent evidence indicates that increased expression of TG2 may prolong cell 
survival by preventing apoptosis [78]. It has been proposed that pro-apoptotic and anti-
apoptotic effects of TG2 strongly depend on its location within the cell. One study has 
shown that cytosolic TG2 is pro-apoptotic while nuclear TG2 diminishes apoptosis [79]. 
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It has been shown that TG2 protein levels in drug-resistant tumour cells is about 
10 times higher than that in drug-sensitive tumour cells [80]. However it is thought that 
these cells are to be able to survive in the presence of high TG2 due to deficient 
intracellular calcium levels [81].  
1.4.5 Structure of TGM2 gene 
The TGM2 gene is composed of 13 exons covering a size of 35kb on the long 
arm of chromosome 20 (20q12) which is expressed as a 3.6kb mRNA in human 
endothelial cells (Figure 1.14) [82]. 
Figure 1.14 Layout of exons in TGM2 
 
Diagram of TGM2 exons drawn to scale.  
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2 Aims 
The aim of this study was to investigate the differential promoter-specific 
pharmacology of Tamoxifen (TAM) in the context of breast cancer cells using TGM2 as 
a model. We analysed the effects of SERMs which are structurally and functionally 
related to TAM. We also aimed to compare the inhibitory activities of TAM on a group 
of ER regulated genes in various breast cancer cell types. To this end we cloned the 
sequence upstream of the TGM2 gene promoter containing the putative nuclear receptor 
response elements and insert it into a luciferase plasmid for use in transient transfection 
assays. 
Specifically we aimed to: 
 Study effects of Tamoxifen and Endoxifen on TGM2 mRNA expression 
 Analyse the requirements of ER or other cellular factors in TGM2 activation 
 Search the TGM2 5‟ flanking region for possible ER binding sites 
 Clone a sequence from this 5‟ region into a luciferase vector 
 Determine the degree of transcriptional regulation of the isolated TGM2 
promoter region by ER and E2/TAM 
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3 Materials and Methods 
3.1 Materials 
3.1.1  Materials used for cell culture 
 Cell culture dishes (100 x 20mm): BD Falcon (Franklin Lakes, NJ ) (cat. 353003) 
 Cell culture plates (12 well): Corning Incorporated (Corning, NY) (cat. T-2989-6) 
 Dulbecco‟s Modified Eagle Medium (DMEM): Invitrogen (Carlsbad, CA), Nutrient 
Mixture F-12 Ham 1X (DMEM/F12 1:1) (cat. 11330) Lot number: 488586, 
supplemented with 8% charcoal stripped fetal calf serum, 0.1 mmol/L nonessential 
amino acids and 1 mmol/L NaPyr. 
 DMEM (Phenol red free): Invitrogen Gibco, Nutrient Mixture F-12 Ham 1X 
(DMEM/F12 1:1) (cat. 21041) Lot number: 495171, supplemented with 8% 
charcoal stripped fetal calf serum, 0.1 mmol/L nonessential amino acids and 1 
mmol/L NaPyr.  
 RPMI 1640 (Invitrogen Gibco): supplemented with 8% fetal bovine serum (FBS) 
(Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM non-essential amino 
acids (Invitrogen) (cat.10-040-CV) Lot number: 10040424 
 RPMI 1640, Phenol red free (Invitrogen Gibco): supplemented with 8% fetal bovine 
serum (FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM non-
essential amino acids (Invitrogen) (cat. 11835) Lot number: 492502 
 Minimum Essential Media (MEM): Invitrogen Gibco supplemented with 8% fetal 
bovine serum (FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM 
non-essential amino acids (Invitrogen)  (cat.11095) Lot number: 539196 
 MEM (phenol red free): Invitrogen Gibco supplemented with 8% fetal bovine serum 
(FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM non-essential 
amino acids (Invitrogen) 
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 Oestradiol (E2): obtained from Sigma Aldrich (St. Louis, MO) 
 Trypsin: Sigma– (0.25% Trypsin – EDTA solution) Lot number: 8J0422 
 100% Ethanol: Pharmaco-AAPER (Brookfield, CT)  
 Dimethyl-sulphoxide (DMSO): Sigma Lot number: 25K2409 
 Tamoxifen (TAM), 4-hydroxytamoxifen (4OHT) obtained from Sigma Aldrich 
 ICI 182,780 (ICI) obtained from Tocris Bioscience (Ellisville, MI) 
 Endoxifen obtained from Ross Weatherman, Purdue University 
 Bazedoxifene, Lasofoxifene and Raloxifene obtained from Wyeth (Madison, NJ) as 
a donation to research. 
 α-Napthoflavine, β-Napthoflavine obtained from Sigma Aldrich 
 All Trans Retinoic Acid (ATRA) obtained from Sigma Aldrich (cat. R2625) 
 Interleukin – 6 (Il-6) obtained from Sigma Aldrich (cat. I3268) 
 50ml tubes: Greiner Bio-One (Monroe, NC) (cat. 227261) Lot number: 08420195 
 TE buffer: (10mM Tris & 1mM EDTA) 
 PBS: Cellgro (Manassas, VA) Dulbeccos Phosphate Buffered Saline (cat. 21-031-
CV) Lot number: 21031303 
 Cells: MCF-7, MDA 231, BT483, HeLa and Skbr-3 obtained from American Type 
Culture Collection (ATCC, Manassas, VA) 
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 Cell lines used in this study, all of which are epithelial tumour cells, are shown 
below: 
Table 3.1 Human cell line used in current study 
Cell line ATCC No Attributes 
MCF-7 HTB-22 ER positive, breast 
MDA-MB-231 HTB-26 ER negative, breast 
BT483 HTB-121 ER positive, breast 
Skbr-3 HTB-30 ER negative, breast 
HeLa CCL-2 ER negative, cervical 
 
 pRST7-ERα expression plasmid (Accession no. X03635) 
3.1.2 Materials used for RNA isolation 
 2-Mercaptoethanol: Sigma Lot number: M3148 
 DEPC water: Omnipur Lot number: 1108B425 
 RNA isolation kit: Bio-Rad (Hercules, CA) Aurum Total RNA Minikit (cat. 732-
6820) Lot number: 7326820 
3.1.3 Materials used for Reverse Transcriptase (RT) PCR 
 Isolated RNA 
 Spectrophotometer: Beckman (Fullerton, CA) DU640  
 PCR Tubes and Strip Caps (8 Strip): Phenix (Candler, NC) (cat. MPX-445) Lot 
number: 080930-800 
 cDNA Synthesis Kit: Bio-Rad iScript (cat.170-8890) Lot number: 92079967 
 Bio-Rad iCycler 
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3.1.4 Materials used for Quantitative PCR 
 cDNA samples 
 qPCR plates: (96 well) Bio-Rad  
 Bio-Rad Microseal „B‟ Film (cat. MSB1001) 
 Sybr Green supermix: Qiagen (Valencia, CA)  
 Bio-Rad iCycler optical system with associated software 
Table 3.2 qPCR primers used for qualitative analysis of mRNA  
 
Forward (5’-3’) Reverse (5’-3’) 
36B4 GGACATGTTGCTGGCCAATAA GGGCCCGAGACCACTGTT 
TGM2 TCACCTTCAGTGTCGTGACC TCCTCTTCCGAGTCCAGGTA 
RET GGATTAAAGCTGGCTATGGCA TGGCTTGTGGGCAAACTTGTG 
pS2 TCCCCTGGTGCTCTATCCTAATAC GCAGTCAATCTGTGTTGTGAGCC 
WISP2 CCTACACACACAGCCTATATC CCTTCTCTTCATCCTACCC 
CYP1A1 TGCAGAAGATGGTCAAGGAG AGCTCCAAAGAGGTCCAAGA 
36B4 qPCR primers span exons 4 & 5, TGM2 primers span exons 2, 3 & 4, RET 
primers span exons 9 & 10, pS2 primers span exons 2 and 3, CYP1A1 primers span 
exons 2 & 3. 
 
3.1.5 Materials used for PCR of genomic DNA 
 DNA isolation: Qiagen DNeasy kit (cat. 69564) Lot number: 42151724 
 MCF-7 cells 
 Isolated DNA 
 Cloned Pfu Turbo: Stratagene (La Jolla, CA) (cat. 600153) Lot number: 
0006037068 
 Pfu buffer (10X): Stratagene (cat. 600153.82) Lot number: 0650189 
 PCR grade water 
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 GC-rich PCR: Clontech (Mountain View, CA) Advantage GC kit (cat. 639114) Lot 
number: 8051025 
 dNTPs (50X) 
 Agarose: Omnipur lot. 0265B068 
 TAE buffer 
 Electrophoresis chamber 
 Ethidium Bromide solution: Bio-Rad– (10mg/ml) (cat. 161-0433) 
 DNA ladder (1kb): Bio-Rad (cat. 170-8204) ) Lot number: L1708204 
 DNA ladder (100bp) GIBCO BRL (cat. 15628-019) Lot number: 1082294 
 Primers obtained from Sigma Aldrich (designed with a 5‟ XhoI binding site) as 
shown in Table 3.3 
  
35 
 
Table 3.3 Sequences of primers targeting regions of TGM2 gene 
Forward-1645 5‟-ATCGCTCGAG GAGCAGTTTCTGCAACAATC-3‟ 
Forward -900 5‟-ATCGCTCGAG GTCTGTTTTTGCAGGTGTGT-3‟ 
Forward -561 5‟-ATCGCTCGAG GCCAGCCGTGTTTGGTG-3‟ 
Reverse +50 5‟-ATCGCTCGAG CCACTGGCGGCGAGAC-3‟ 
Reverse -305 5‟-ATCGCTCGAG CCCTCATAGAAACACACAACG-3‟ 
Reverse -540 5‟-ATCGCTCGAG CCACAGTTACACCAAACACG-3‟ 
  
F-690 5‟-ATCGCTCGAG TCTGGACACCTGCTCATCTG-3‟ 
R-480 5‟-ATCGCTCGAG GCAGACACACCAAGACAGGG-3‟ 
F-1200 5‟-ATCGCTCGAG GGCTGCTATGGTCATTTCC-3‟ 
R-exon9 5‟-ATCGCTCGAG GTCCCTGGCAGAGGTAGAAA-3‟ 
F+exon9 5‟-ATCGCTCGAG GGGTATGTGCCCTCAGAGTCTT-3‟ 
R+700 5‟-ATCGCTCGAG GGGCTAAGGCTGTGTTTTACT-3‟ 
F-UBS 5‟-ATCGCTCGAG GGCTTTGAGATTGGACTGC-3‟ 
R-UBS 5‟-ATCGCTCGAG GGCCTGGACTTAGTTCATTACA-3‟ 
  
F_UBS-560 5‟-AACCCTCGAG GTGGTAGGAACAAAGCCATTG-3‟ 
R_UBS+550 5‟-AACCCTCGAG CACCAGCTCCATTCTGAACA-3‟ 
F_ERE-1120 5‟-GGAACTCGAG CTGTGAGGGAGGGATTCTTT-3‟ 
R_ERE+440 5‟-GGAACTCGAG CGGACAGGGACACACAACTA-3‟ 
All primers have an XhoI binding site motif (CTCGAG) (in red) with a 4 bp spacer (in 
blue) tagged to the 5‟ end. Primers are named by the distance in bp to their relevant 
putative ER binding region; either within the 5‟binding region, 3kb upstream or within 
exon 9. (F, Forward; R, Reverse; UBS, upstream binding sequence) 
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3.1.6 Materials used for cloning of DNA fragments 
 PCR purification kit: GeneScript (Piscataway, NJ) (cat. L00198) Lot number: 
PP00107  
 DNA extraction kit: GeneScript gel (cat. L00199) Lot number: GE00107 
 XhoI restriction enzyme: New England Biolabs (Ipswich, MA) (cat. R0146S) Lot 
number: 54 
 HindIII restriction enzyme: New England Biolabs (cat. R014S) Lot number: 66 
 BglII restriction enzyme: New England Biolabs (cat. R0144S) Lot number: 40 
 KpnI restriction enzyme: New England Biolabs (cat. R0142S) Lot number: 51 
 SacI restriction enzyme: New England Biolabs (cat. R0156S) Lot number: 49 
 RE buffer #1: New England Biolabs (cat. B7001S) Lot number: 1007 
 RE buffer #2: New England Biolabs (cat. B7002S) Lot number: 03064 
 RE buffer #3: New England Biolabs (cat. B7003S) Lot number: 1107A 
 RE buffer #4: New England Biolabs (cat. B7004S) Lot number: 0030805 
 pGL4.26 vector (luc2/minP/Hygro): Promega (Madison, WI) (cat. E8441) 
 Shrimp Alkaline Phosphatase (SAP) 
 SAP buffer 
 T4 DNA ligase: New England Biolabs (cat. M0202L) Lot number: 1910801 
 T4 DNA ligase buffer: New England Biolabs (cat. B0203S) Lot number: 0303 
 SOC media: Invitrogen (cat. 460821) Lot number: 470041 
 LB broth 
 DH5α cells 
 XL2-Blue Ultracompetent cells: Stratagene (cat.200150) Lot number: 0006039741 
 Miniprep kit: GeneScript (cat. L00193) lot. MM00107 
37 
 
  Plasmid Maxiprep kit: Qiagen Qiafilter (10) (cat. 12262) Lot number: 
ANL1012/BRL023/L02/133 
3.1.7 Materials used for transfections 
 Opti-MEM Reduced Serum Media (cat.11058) Lot number: 544027 
 Lipofectin Transfection Reagent: Invitrogen  (cat. 18324-020)  
 Luciferase substrate: Lucferin 
 β-gal substrate: chlorophenol red β-D-galactopyranoside (CPRG) Oz Biosciences 
(cat: GC10002) 
 Dithiothreitol (DTT) obtained from Sigma Aldrich (D9779) 
 Microplate Analyser: Fusion™ Universal (PerkinElmer) 
 96 well plates: Corning (cat.3596)  
 96 well luminometer plates: Optiplate  
 Expression vectors: 
o pCMV-βGal 
o pRST7ERα  
o pRST7ERβ 
 Reporter constructs: 
o 3xERE-TATA-luc 
o TGM2-luc 
 Software programs 
o Microsoft Excel 
o CLC Main Workbench 5 
o Geospiza Finch TV 1.4 
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3.2 Methods 
3.2.1 Mammalian Cell Culture  
All cell lines were obtained from American Type Culture Collection (Manassa, 
VA) and cultured in media from Invitrogen (Carlsbad, CA). HeLa cells were maintained 
in MEM, MCF7 cells in DMEM/F12 and SKBR3 and BT483 cells in RPMI 1640, each 
supplemented with 8% charcoal-stripped foetal bovine serum (FBS) (Hyclone 
Laboratories, Logan, UT), 1mM sodium pyruvate, and 0.1mM non-essential amino 
acids (Invitrogen).  All cell lines were propagated in a 37˚C incubator with 5% CO2. 
3.2.2 Hormone/inhibitor treatment assays 
One ml of 2x105 cells/ml in phenol red free media was plated in each well in 12 
well plates. All ligand stocks were dissolved in ethanol or DMSO before use in cell 
culture. After 2-day incubation cells were treated with a 10x concentration of hormone 
or inhibitor diluted in spent media. 100µl of the 10x concentration of the appropriate 
hormone/inhibitor treatment were added to each well and incubated for 8 hours (unless 
otherwise stated). E2 was used in 10ng/ml concentration while all pharmacological 
agents were used in concentrations ranging from 10nM to 1µM. After incubation cells 
were washed in PBS and lysed with RNA lysis solution (Bio-Rad). 
3.2.3 RNA isolation, cDNA preparation and quantitative PCR 
Total RNA was isolated from cells using Bio-Rad Aurum Total RNA Mini Kit 
according to the manufacturer‟s instructions, which included a DNase step. One µg of 
RNA was reverse transcribed into cDNA using the Bio-Rad iScript cDNA synthesis kit 
according to the manufacturer‟s instructions. In all cases, a cDNA reaction lacking 
reverse transcriptase was performed to monitor possible genomic DNA contamination. 
The Bio-Rad iCycler Real-time PCR System was used to amplify and quantitate the 
levels of target gene cDNA. Quantitative PCR (qPCR) reactions were performed using 
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8µl of diluted cDNA (1:15), 10uM specific primers and Qiagen SYBR green supermix 
in a total volume of 13ul. The following cycling protocol was used for all reactions: 1 
cycle at 95°C for 5 min, followed by 40 cycles consisting of 95°C for 15 sec, 60°C for 
30 sec and 72°C for 30 sec. A final cycle at 72°C for 7 min followed. A melt curve 
analysis from 70-90°C (0.5°C/10 sec increments) was performed for all reactions to 
detect primer dimers or other transcripts. A single PCR product was detected in all 
cases. Each cDNA reflecting each biological sample were run in triplicate and 
expressed as an average +/- SEM. 
3.2.4 Plasmids 
3.2.4.1 Expression plasmids 
The pRST7-ERα plasmid is a CMV - driven expression plasmid containing 
amino acids 1-595 of the full length human ER [19]. The pRST7-ERβ plasmid is a 
CMV driven expression plasmid containing amino acids 1-477 of the full length human 
ERβ [83]. pCMV-β-Gal (obtained from Clontech, Palo Alto, CA) is a mammalian 
vector expressing a β-galactosidase gene driven by the human cytomegalovirus 
immediate early gene promoter.  
3.2.4.2 Reporter constructs 
The pTGM2-luc plasmid (Figure 3.2) was constructed as follows:  an empty 
pGL4.26 plasmid (Figure 3.1) (obtained from Promega) was digested with XhoI and 
ligated to a 1.7kb fragment (previously digested with XhoI) spanning the TGM2 
regulatory element isolated from gDNA. The sequences of the oligonucleotides were: 
forward 5‟-GGAACTCGAGCTGTGAGGGAGGGATTCTTT-3‟ and reverse 5-
GGAACTCGAGCGGACAGGGACACACAACTA-3‟. The following PCR protocol 
was used: 1 cycle at 95°C for 2 min, followed by 32 cycles consisting of 95°C for 30 
sec, 62°C for 40 sec and 72°C for 2 min. A final cycle at 72°C for 5 min followed. The 
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ligated plasmid was transformed into XL2-Blue ultracompetent cells and grown at 37°C 
overnight on Ampicillin plates. Colonies were re-cultured in 10mls of LB broth + 200µl 
Ampicillin (1mg/ml) at 37°C overnight. Plasmid isolation was performed on 1ml of 
transformed XL2 cells according to the manufacturer‟s instructions. Isolated plasmids 
were XhoI digested to identify clones with the insert. The correct orientation was 
confirmed by analysis of the restriction fragment length using HindIII and BglII. A 
large plasmid isolation was used to isolate 1ml of purified pTGM2-pGL4.26 plasmid. 
3xERE-TATA-luc is a luciferase reporter vector containing three tandem repeats 
of the consensus ERE upstream of the human TATA promoter sequence inserted into 
the multiple cloning site of pGL3-basic vector. 
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Figure 3.1 pGL4.26 vector, obtained from Promega 
 
Map of pGL4.26 plasmid obtained from Promega, showing β-lactamase gene 
(Ampicillin resistance), luciferase reporter gene (luc2), multiple cloning region 
containing XhoI restriction site, minimal promoter (TATA box) and mammalian 
selectable marker (hygromycin). 
 
Figure 3.2 TGM2-luc plasmid 
 
Map of cloned TGM2-luc plasmid with Ampicillin resistance gene (β-lactamase), 
luciferase reporter gene (luc2) and the TGM2 insert (5‟ flanking region) 
 
  
TGM2 insert 
XhoI 
β-lactamase (Amp R) 
XhoI 
Minimal Promoter 
Luc2 reporter gene 
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3.2.5 Mammalian Cell Culture and Transfections 
 All cells were plated in phenol red free media in 24-well plates 24h prior to 
transfection. Cells were transfected in OptiMEM I Reduced Serum Medium 
(Invitrogen) with 3μg of total plasmid per triplicate sample in 24-well, using 
Lipofectin® according to manufacturer‟s protocol (Invitrogen). 100ng of the pCMV-
ßGal normalization vector was used with 0, 10 or 20ng of ERα expression vector and 
luciferase reporter constructs making up the remaining. DNA-Lipofectin mix was added 
and incubated for 4 h. All ligand stocks were dissolved in ethanol or DMSO before use 
in cell culture, and cells were treated with ligands added to phenol-red-free media. A 
saturating concentration of ligand was added to the cells 20-24 hr prior to assays: 10nM 
E2, 1µM 4OHT, 1µM ICI, 100ng/µl IL-6 or 1µM ATRA (All Trans Retinoic Acid). 
Cells were lysed 24-28hrs after transfection and assayed for luciferase and -
galactosidase activities using a Fusion™ Universal Microplate Analyzer (PerkinElmer).  
Results are expressed as normalized luciferase activity (NLA, normalized with gal for 
transfection efficiency)  SD per triplicate sample of cells. Statistic analysis was 
performed on these results using the t-test to compare the difference between two 
groups of data. 
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4 Results 
4.1 Background 
4.1.1 Oestrogen Receptor Signaling in the Breast 
Oestrogens function as mitogens in most ER-positive breast cancers. Upon 
ligand binding, ER undergoes a conformational change that results in dimerisation, 
DNA binding, recruitment of transcriptional coregulators, and modulation of target gene 
expression. The implication of oestrogens and ER in breast cancer has led to the 
pharmaceutical development of SERMs and anti-oestrogens.  SERMs exhibit tissue- 
and promoter-specific agonist and antagonist behaviour. The unique and compound-
specific conformational change in ER induced by SERM binding allows different 
protein-protein interaction surfaces to be exposed, leading to differential recruitment of 
co-regulatory proteins and thus diverse biological outcomes. The ER regulates a large 
set of genes in the breast cancer cell. Genes activated by the ER are generally involved 
in proliferation and cell survival while genes inhibited by ER are generally involved in 
halting the cell cycle. Therefore SERMs prevent the growth of breast cancer cells by 
inhibiting ER-regulated genes.  
It is not fully known however how a patient on TAM develops a de novo or an 
acquired resistance to the drug. Therefore understanding the biology of ER/TAM 
control of gene expression is critical to understanding how resistance to TAM may 
develop. As described in the introduction, TG2 expression has been shown to be up-
regulated in drug-resistant and metastatic breast cancer cells and is thought to contribute 
to TAM resistance [84]. 
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4.2 ER control of TGM2 expression 
It has been previously shown that E2 activates the TGM2 gene. As discussed 
earlier TGM2 is involved in many processes within the cell. As TGM2 is an ER-
regulated gene, we would expect this gene to be inhibited by TAM.  
In this study, we focused on defining the molecular mechanisms underlying 
TAM inhibition of TGM2 in the context of breast cancer cells. 
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4.2.1 Time-course of ligand treatments on TGM2 expression 
Our first objective was to evaluate the activation of TGM2 by E2 in MCF-7 cells 
over a 6 hr time-course. The concentrations of each ligand required were examined in 
the next experiment; however for this experiment we used physiologically relevant 
ligand concentrations. [85] Also cells were treated with 4OHT and β-Napthoflavone 
(BNF) over a six hour time-course as these were used in later experiments. BNF is an 
Aryl Hydrocarbon receptor agonist and is used is this study to investigate the effects of 
TAM on AhR-controlled genes. This experiment aims to identify the length of 
incubation required for optimum gene activation and mRNA production. pS2 (trefoil 
factor 1), an ER-regulated gene highly expressed in breast cancer cells, was used here as 
a positive control. Figure 4.1 shows the plate setup for this experiment.   
 
Figure 4.1 Plate setup for MCF-7 cell culture 
 
 
 
 
 
1ml of 2x10^5 MCF-7 cells/ml were plated in 15 wells of two 12 well plates. Cells were 
diluted in phenol red free DMEM//F12 media (+8% CFS with NEAA and Na Pyruvate) 
Cells were incubated for 48hrs to achieve confluency. Dilutions of ligands were made 
up in spent media and added to the appropriate wells to make to make a final volume of 
1ml/well.  
 
After the incubation period, RNA was isolated from each cell culture well and 
quantified. Table 7.1 UV quantification of isolated RNA (Raw data) shows the UV 
quantification values for each of the RNA samples. The volume of isolated RNA 
1hr 2hr 4hr 6hr 6hr 
Control 
E2 + 
4OHT 
E2 + 
BNF 
10nM E2  
100nM 4OHT  
100nM BNF  
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required to give 1µg/well in the iScript Reverse Transcriptase reaction was calculated 
by dividing 1µg by the concentration of RNA (µg/ml).    
Each well in the Reverse Transcriptase (RT) reaction contained 1µl Reverse 
Transcriptase enzyme (iScript), 1µg of RNA and made up to a final volume of 16µl 
with RNase-free water (Table 7.2). A no-RT (NRT) control also was set up as a 
negative control which contained RNA but no RT enzyme. The RT samples were run on 
a single PCR cycle according to manufacturer‟s instructions.  
  The cDNA produced in the RT reaction was subjected to real-time PCR 
(qPCR) for quantification. In addition to the 15 samples and NRT, a set of standards 
were set up. This was done by pooling 1µl from each cDNA sample (15µl) and diluting 
the cDNA in a set of serial dilutions to give 1x, 0.2x, 0.1x and 0.02x concentrations. 
Each sample was run in triplicate for each of the primers analysed. An example of the 
qPCR results are presented in Figure 4.2, which shows the data for 36B4 and TGM2 
analysis. 36B4 is a house-keeping gene which is transcribed at a constant rate, 
regardless of cell treatments. It is analysed as an internal standard for the purpose of 
normalising qPCR data.  
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Figure 4.2 PCR quantification curve for 36B4 and TGM2 primers 
PCR cycle number (X-axis) and fluorescence (Y-axis). The graph shows the increasing 
uptake of Sybr green (fluorescent dye) as it binds amplified dsDNA in each well. Sybr 
green fluoresces intensely while intercalated in the minor groove of double stranded 
DNA. The cycle at which the amount of fluorescence exceeds a threshold value (orange 
line) is known as the CT (Threshold cycle). The CT relates to the concentration of cDNA 
present at the start of the run. The first set of curves to cross the threshold line 
represents analysis of 36B4, followed by curves for TGM2 analysis. The earlier the 
curve crosses the threshold, the higher the amount of cDNA present at the start of the 
run. 
  
 
The first set of data on the graph to cross the threshold value is 36B4, followed by 
TGM2. This means that 36B4 is in higher concentration than TGM2. The CT values for 
each sample are exported to a spreadsheet for analysis. For each primer used in the 
qPCR experiments a melt curve (Figure 4.3) and a standard curve (Figure 4.4) is 
performed. Upon completion of the PCR reaction a melt curve was performed to test for 
the presence of primer dimers or contaminating primers. The presence of a single peak 
on the melt curve for each primer confirms the presence of a single PCR product. The 
results of this analysis are presented in Figure 4.3. 
  
36B4 
TGM2 
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Figure 4.3 Melt curve for 36B4 and TGM2 primers 
 
The melt curve shows the temperature dependent dissociation between two DNA 
strands, in this case the amplified product. The dissociation of the DNA during heating 
is measureable by the large reduction in fluorescence that results. The graph shows the 
change in fluorescence (y-axis) vs. temperature (x-axis) for 36B4 and TGM2 amplified 
products. The melt curve is useful for determining the specificity of the primers used as 
primers may induce primer-dimer formation or amplify other non-specific products. The 
presence of a single peak for each primer indicates that no primer dimer or other non-
specific products have been produced. 
 
The results of the melt curve indicate that the PCR reaction has no 
contamination and that single product was formed. A standard curve is also performed 
for each qPCR reaction in this study which is used to examine PCR efficiency. The 
standard curve is presented in Figure 4.4. The graph shows there is a direct correlation 
(r = 0.998) between the relative log concentrations of the samples/standards and the 
threshold cycle. The unknown sample (in red) is the NRT which has practically no 
detectable cDNA. 
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Figure 4.4 qPCR Standard curve for 36B4 
 
 
The relative starting concentrations of cDNA (x-axis) are graphed against the threshold 
cycle (y-axis) for each of the standards. The graph shows the standards (in blue) 
analysed in this experiment. The NRT samples were run as a negative control (in red). 
The slope of the curve is directly related to the efficiency of the PCR reaction. At a PCR 
efficiency of 100% the template DNA doubles after each cycle during exponential 
amplification.  
 
The relative gene expression for each sample was calculated according to the 2^-
ΔΔCT method using Microsoft Excel [86]. This method normalises the CT from each 
sample to its untreated control, which is then normalised again to its respective 36B4 CT 
value to give a ΔΔCT value. 36B4 is used in this study to normalise all other genes as its 
expression remains unchanged regardless of cell treatments. The fold change in gene 
induction is given by the formula 2^-ΔΔCT. 
The results for the assay described in Figure 4.1 are presented in Figure 4.5. In 
this experiment the cells were treated with no ligand (control), E2, 4OHT, BNF, or 
combinations of the ligands prior to RNA isolation, RT-PCR and qPCR for 36B4, 
TGM2 and pS2. 
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Figure 4.5 Time-course of gene expression in MCF-7 cells  
 
 
MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10nM E2, 100nM 
4OHT, 100nM BNF for 1, 2, 4 or 6hr intervals. Cells were harvested and cDNA 
prepared from isolated RNA was subjected to qPCR analysis. qPCR was performed to 
analyze TGM2, pS2 and 36B4 gene expression. Data are normalized to the 36B4 gene 
and expressed as mean fold change over vehicle ± SEM for triplicate amplification 
reactions. All qPCR data in this study was calculated using the 2-ΔΔCT method to 
produce a normalised fold change [86]. Asterisks: unpaired two-tailed T-test, * p value 
> 0.05 (no significant difference), ** p value < 0.01. 
 
The qPCR results show that incubating the cells with ligand for 6 hrs after 
ligand treatment is sufficient for TGM2 (A) and pS2 (B) mRNA up-regulation. BNF or 
4OHT do not activate transcription of these genes. Treatment of E2 in combination with 
4OHT inhibits E2 induced pS2 mRNA expression but not TGM2. Statistical analysis 
using the Students t-test shows no significant difference (p<0.01) between TGM2 
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mRNA expression in either E2-treated or E2/4OHT co-treated cells. This finding 
suggests that 4OHT is unable to inhibit E2-induced TGM2 mRNA expression. The next 
objective was to identify the concentration of ligands that are required for optimum 
gene transactivation.  
4.2.2 To determine optimum ligand concentrations for TGM2 mRNA 
expression 
Determining the required concentration of ligands for activation of gene 
transcription is also required for future pharmacological experiments. RET (RET proto-
oncogene) is used here as a positive control (ER-regulated gene). All qPCR experiments 
were performed as outlined in experiment 4.2.1. 
Figure 4.6 Dose-response curve of TGM2 induction.   
  
 
MCF-7 cells were treated with increasing concentrations of E2( 0.1 - 100nM), 
4OHT (10 - 1000nM). Cells were harvested and cDNA prepared from isolated 
RNA was subjected to qPCR analysis.  Data are normalized to 36B4 and 
expressed as mean fold change over vehicle ± SEM for triplicate amplification 
reactions. 
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The qPCR results for TGM2 show a high standard error which may suggest a 
problem with the PCR protocol or polymerase enzyme stability. The DNA polymerase 
enzyme may have been allowed to reach room temperature prior to the start of the 
qPCR run, resulting in imprecise data. The results do show however that between 1-
100nM E2 is sufficient for activation of RET and TGM2. A concentration of 10nM E2 
and 1µM 4OHT and an incubation time of 6 hours was chosen for future experiments.  
4.2.3 TAM fails to inhibit ER-activation of TGM2 
Results presented in Figure 4.5 indicate that 4OHT fails to inhibit E2-induced 
up-regulation of TGM2; this experiment was repeated using 4OHT and a SERD, ICI as 
a pharmacological control. RET is used as a control E2-regulated gene. ICI works 
through a different mechanism than TAM, by inducing rapid degradation of ER.  
 
Figure 4.7 E2-induced activation of TGM2 is not inhibited by TAM 
 
  
MCF-7 cells were treated with vehicle (control), 10nM E2 with either 1µM 4OHT or 
1µM ICI for 6hr. Cells were harvested and cDNA prepared from isolated RNA was 
subjected to qPCR analysis. Data are normalized to 36B4 and expressed as mean fold 
change over vehicle ± SEM for triplicate amplification reactions from one 
representative experiment. Asterisks: unpaired two-tailed Student‟s T-test, * p value > 
0.05 (no significant difference), ** p value < 0.01. 
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The results show that both RET and TGM2 are both induced by E2. However 
4OHT treatment in combination with E2 resulted in a significant decrease in RET 
expression, while no significant decrease in TGM2 expression was observed. Statistical 
analysis using the Student‟s t-test shows that there is a significant difference (p <0.01) 
in RET gene expression between E2 and E2/4OHT treated cells whereas there is no 
difference (p >0.05) in TGM2 expression between E2 and E2/4OHT treated cells. This 
suggests that TAM is unable to inhibit E2-mediated activation of TGM2. ICI however is 
able to fully inhibit E2-induced activation of both TGM2 and RET.  
SERDs work by inducing rapid re-compartmentalisation and degradation of ERα 
protein while SERMs block ligand induced activation of the ER. This indicates that 
TAM is binding the ER and preventing transcription of RET but not TGM2. ICI is able 
to inhibit TGM2 transcription since it leads to degradation of the ER. This left us with 
the task of investigating why TGM2 is not inhibited by TAM when other ER-regulated 
genes are, and what is the possible biological significance of this.  
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4.2.4 Is ER required for TGM2 up-regulation? 
In the following set of experiments we examined the role of some of the cellular 
factors required for the up-regulation of TGM2. We have already shown that E2 is 
required for activation of this gene (Figure 4.5). This experiment investigates the role of 
ERα in TGM2 activation. 
Transfection of an ERα plasmid into MDA-231 cells is used to identify the role 
of ERα in TGM2 induction. MDA-231 (ER negative) breast cancer cells were 
transfected with the ERα expression vector. Cells are treated with E2 and with 4OHT in 
combination with E2. qPCR was performed using primers for WISP2 (WNT1 inducible 
signaling pathway protein 2), an ER responsive gene, 36B4, and TGM2. βgal is used as 
a negative control as it does not have a canonical ER binding site and is not activated by 
oestrogen signalling. 
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Figure 4.8 ERα transfection of MDA-231 cells  
 
 
 
MDA-231 cells treated with either ERα expression vector or βGal (negative control) 
and treated with 10nM E2 in combination with either control (V) or 1µM 4OHT. Cells 
were harvested and cDNA prepared from isolated RNA was subjected to qPCR 
analysis.  Data are normalized to the 36B4 gene and expressed as mean fold change over 
vehicle ± SEM for triplicate amplification reactions. Asterisks: unpaired two-tailed T-
test, * p value < 0.01. 
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WISP2 qPCR data show good E2-induced activation of transfected ERα 
confirming that ER activates WISP2 and ER transfection was successful. Statistical 
analysis using the Student‟s t-test shows there is a significant difference (p <0.01) 
between TGM2 induction in cells treated with E2 which have the ERα over cells treated 
with βgal. The results however do show poor activation of TGM2 which may be due to 
inadequate RT/qPCR efficiency or insufficient ERα transfection. These results further 
confirm that TGM2 is an E2-regulated gene. The addition of 4OHT to cells treated with 
E2 and transfected with the ERα plasmid induces an inhibition of WISP2 while having 
no effect on TGM2 mRNA expression. These results also confirm data from previous 
experiments where TAM is unable to inhibit E2-induced up-regulation of TGM2. 
To understand why this gene is not inhibited by TAM we must examine the 
involvement of other cofactors which may be preventing this inhibition. The following 
experiment examines the possible role of the Aryl Hydrocarbon Receptor (AhR) in 
preventing TAM inhibition of TGM2. We hypothesized that activated AhR prevents ER 
inhibition of the TGM2 gene by a process which is distinct from other ER regulated 
genes. The following experiment investigates the role of TAM on the AhR and the 
effects of activated AhR on transcription of the TGM2 gene. The aim of this is to 
investigate if TAM activation of AhR is responsible for the continued up-regulation of 
TGM2 in the presence of E2 and TAM through the process of AhR-ER cross-talk.  
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4.2.5 Tamoxifen activates the Aryl Hydrocarbon receptor (AhR) 
It has been previously shown that TAM can activate CYP1A1, an AhR (Aryl-
Hydrocarbon Receptor) regulated gene independently of the ER [87]. MCF-7 cells are 
treated with E2, 4OHT and BNF over a 6 hour time-course. BNF (β-Napthoflavone), an 
AhR agonist, is used here as a positive control. 
 
Figure 4.9 Dose-response curve of TGM2 induction.   
 
MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10 nM E2, 100nM 
4OHT, 100nM βNF for 1,2,4 or 6hr intervals. Cells were harvested and cDNA prepared 
from isolated RNA was subjected to qPCR analysis.  Data are normalized to the 36B4 
gene and expressed as mean fold change over vehicle ± SEM for triplicate amplification 
reactions. 
 
Results presented in Figure 4.9 show that 4OHT and βNF (positive control) will 
activate the CYP1A1 gene (at an optimum incubation of 4 hr) confirming that 4OHT 
does activate AhR as an off-target effect. This is where a drug binds to and activates a 
receptor which is not its intended target.   
  
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
- 1hr 2hr 4hr 6hr 1hr 2hr 4hr 6hr 1hr 2hr 4hr 6hr 6hr 6hr
control 10nM E2 100nM 40HT 100nM BNF E2 + 
4OHT
E2 + 
BNF
N
o
rm
a
li
se
d
 F
o
ld
 C
h
a
n
g
e
CYP1A1
58 
 
In previous experiments we have shown that ER is required for TGM2 gene 
expression. However because TAM activates AhR, we must also investigate if AhR is 
capable of maintaining TGM2 gene expression in the presence of TAM. To do this we 
treated MCF-7 cells with ligands which activate the AhR and measured subsequent 
TGM2 mRNA expression.  
Figure 4.10 shows the effects of the AhR-activating ligands, TAM and BNF on 
TGM2 mRNA expression. These results show that treatment of MCF-7 cells with AhR 
ligands alone is not sufficient maintain to mRNA expression of TGM2. The data from 
this experiment show that activated AhR alone is unable to activate this gene. 
 
Figure 4.10 Effects of AhR ligands on TGM2 activation.  
 
MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10 nM E2, 100nM 
4OHT, 100nM βNF for a 6hr incubation. Cells were harvested and cDNA prepared 
from isolated RNA was subjected to qPCR analysis.  Data are normalized to the 36B4 
gene and expressed as mean fold change over vehicle ± SEM for triplicate amplification 
reactions. 
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4.2.6 Array of SERMs on TGM2 activation 
Although we have shown that TAM cannot inhibit E2 induced TGM2 mRNA 
expression, we sought to determine whether structurally related breast cancer drugs 
show similar results. In this experiment we analysed the effects of an array of SERMs 
and SERDs on E2-mediated activation of TGM2.  
Figure 4.11 Effect of SERMs on TGM2 activation 
 
 
 
MCF-7 cells were treated with vehicle (control) or 10 nM E2 and either 1µM ICI, 
4OHT, Tamoxifen, Endoxifen, Raloxifene, Lasofoxifene or Bazedoxifene and incubated 
for 8hr. Cells were harvested and cDNA prepared from isolated RNA was subjected to 
qPCR analysis. Data are normalized to 36B4 and expressed as mean fold change over 
vehicle ± SEM for triplicate amplification reactions. 
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These data are the first indication that Endoxifen (Endox) is also unable to 
inhibit TGM2. As stated earlier Endoxifen, a secondary metabolite of 4OHT is as potent 
as 4OHT with respect to ER binding and inhibition of E2 induced cell proliferation. 
However in this experiment we did not achieve full inhibition of the control gene RET; 
this may be due the poor solubility of some of these drugs in media. Also Tamoxifen is 
known to undergo spontaneous rearrangement from its trans to cis forms resulting in a 
weak anti-oestrogen. A dramatic solvent effect has been observed on the rate of the 
process of molecular rearrangement [88]. This may explain the lowered efficacy of 
Tamoxifen in these set of results. To help overcome these solubility issues we used 
serial dilutions when diluting ligands, while all ligands were kept on ice.  
  
61 
 
4.3 Cloning TGM2 response elements 
At this point we have displayed the differential pharmacology of TAM on ER 
activation of TGM2 in the context of breast cancer cells. The cell culture assays have 
shown us that TAM is unable to inhibit E2/ER-induced activation of TGM2 while other 
agents such as ICI fully inhibit this activation. The next step in this study is to 
investigate the genetic requirements for E2 activation of TGM2. This involves cloning a 
short segment of the promoter region into a Luciferase plasmid for use in cell 
transfection assays. By designing primers to different response elements on the TGM2 
promoter we can clone these regions and investigate the precise sequence requirements 
of the ER/E2/TAM activation complex.  
The first step is to perform a bioinformatics study on the TGM2 DNA sequence. 
The entire genomic sequence for chromosome 20 was downloaded 
(www.bioinfo.ut.ee/HMgenome/CEU) and the exons/introns located along with the 
putative ERE. 
Figure 4.12 Layout of exons on TGM2 
 
 
Exons within the TGM2 gene are labelled 1 to 13, drawn to scale. 
 
The putative ERE and AP-1 sites were found by performing a nucleotide 
sequence search using Bio-informatics software (CLC Main Workbench 5.0) 
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Figure 4.13 Putative ER binding regions in the TGM2 promoter 
 
 
A further literature search highlighted two other possible ER binding regions on 
the TGM2 gene based on a genome-wide study of ER binding sites (Figure 4.14). [35] 
These regions which were identified by chip-on-chip analysis located the binding sites 
to within 600bps. One is located 3kb upstream of the transcription start site (Figure 
4.16), while the other is located within exon 9 (Figure 4.17). There are also three SP-1 
sites located just upstream of the gene promoter which may also indirectly drive ER-
mediated transcription. 
Figure 4.14 Location of ER binding sites 
 
 
 
Data concerning the locations of these ER binding sites was downloaded from the 
supplemental data supplied with the published data on the Harvard University website 
(http://research.dfci.harvard.edu/brownlab/datasets/index.php?) [35] 
 
The next step was to design a series of primers to cover the TGM2 regulatory 
region and the two putative ER binding sites shown above. All primers were produced 
with an Xho1 cutting site on the 5‟ end for ligating the PCR products into the Luciferase 
vector. The list of primers is outlined in the Materials and Methods section (Table 3.3). 
These were named by their relative position to the transcription start site (Figure 4.15). 
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Different combinations of these forward and reverse primers can be used to amplify the 
required sequences.  
Figure 4.15 Location of primers on TGM2 5’ flanking region 
 
 
Primers were designed to a length of 20bps with a GC content of 45-55% and an 
annealing temperature of 55-60°C. All primers have an Xho1 binding site attached. 
 
Figure 4.16 Location of primers on upstream putative ER binding site 
 
 
 
 
Figure 4.17 Location of primers on Exon 9/ER binding site 
 
 
Primers were designed spanning the putative ER binding region and exon 9. An extra 
set of primers located on either side of the exon gave the option of isolating the region 
upstream or downstream of the exon. Primers are named relative to their position to the 
putative ER binding site. 
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4.4 PCR of genomic DNA 
Having designed the primers, PCR reactions were set up in order to amplify the 
particular DNA elements. Genomic DNA was isolated from MCF-7 cells. PCR was first 
performed with the primers targeting the full length (1.7kb) TGM2 regulatory region as 
in Figure 4.15. The PCR protocols used are described in the Materials and Methods. 
PCR amplification of the full length TGM2 regulatory region was first performed using 
the primers “Forward-1645” and “Reverse +50” in a temperate gradient PCR cycle 
(Figure 4.15). Repeating this protocol with the addition of varying amounts of DMSO 
(Dimethyl Sulfoxide) (1-7%) and the use of either Pfu Turbo enzyme or GC Advantage 
2 polymerase did not result in any visible bands (Figure 4.18). In the process of 
optimising PCR conditions, PCR was repeated for all combinations of forward and 
reverse primers surrounding the putative ERE (Figure 4.15) and run on agarose gel, 
however no visible specific bands were produced. 
 
Figure 4.18 PCR amplification of full length TGM2 regulatory region 
 
  
Agarose gel of PCR amplified gDNA using the temperature gradient 48-60°C. ML, 1kb 
DNA molecular weight ladder. 
 
  
ML 48° 60° ML Temp. 
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After redesigning primers for this region (“ERE-1120” and “ERE+440”) (Figure 
4.15), this protocol was repeated with the new set of primers with increasing 
concentrations of DMSO (0, 3 and 5%) and at temperature gradients of 56-66°C.  
 
Figure 4.19 PCR amplification of full length TGM2 regulatory region 
 
 
 
  
 
0% DMSO (A) shows unspecific bands, PCR preformed at gradient temperature (56-
66°C). Addition of 3% or 5% DMSO (B) and (C) gives a specific band at 1.7Kbps. This 
sequence is be referred to as pTGM2 (TGM2 promoter) in the following experiments.  
 
The specific bands were cut from the gel and the DNA isolated. This sequence 
contains the 5‟ TGM2 regulatory region containing the putative ERE and AP-1 sites as 
shown in Figure 4.13. With the isolated DNA as a template (pTGM2), we used a 
separate set of primers (“Forward 561” to “Reverse 305”) which target a short sequence 
within the template sequence in a PCR reaction (Figure 4.15). This was done to confirm 
that the correct sequence was amplified from genomic DNA.  
  
B 
A 
C 
0% DMSO 
3% DMSO 
5% DMSO 
ML 56° 66° ML 
1 2 3  4  5  6  7 8 
1.7 kb 
1.7 kb 
1.7 kb 
Temp. 
66 
 
Figure 4.20 PCR amplification of a 250bp sequence using pTGM2 as a template 
 
 
The amplified sequence from primers “ERE-1120” and “ERE+440” (pTGM2) was used 
as a DNA template in this reaction. Primers used were “Forward 561” to “Reverse 305”. 
The presence of PCR products (shown in triplicate) proves that the correct 1.7kb 
sequence was amplified (Figure 4.19)  
  
PCR was performed using the primers “Forward-690 and Reverse-480” and the 
pTGM2 sequence as a template (Figure 4.15). The target sequence contains the putative 
ERE, located about 650bps upstream of the transcription start site (Figure 4.13). PCR 
was performed at a temperature gradient of 52-60°C.  
Figure 4.21 PCR amplification of putative ERE at position -650bp 
 
 
PCR products were run on 1% Agarose gel with a 100bp molecular ladder. Product size 
is 220bps including the XhoI binding sites attached to either end. This sequence 
contains the putative ERE as described earlier.  
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In order to amplify the downstream putative ER binding site (Figure 4.17), PCR 
was performed on gDNA using primers targeting a 1.9kb sequence on exon 9 using the 
primers “Forward-1200” and “Reverse+700”. A temperature gradient from 46-58°C 
was set up on the PCR thermocycler in order to find the optimum primer annealing 
temperature (Figure 4.22).   
Figure 4.22 PCR amplification of 1.9kb of TGM2 exon 9  
 
 
PCR reaction was performed at a temperature gradient of 46-58°C. Products were run 
on 0.75% Agarose gel (+Ethidium Bromide) with 1kb molecular ladder. 
The PCR products from the most specific bands (at 46-50°C) were isolated and 
Xho1 digested for ligating into the Luciferase vector in later experiments. To isolate the 
upstream putative ER binding site (Figure 4.16), PCR was performed using the primers 
“Forward UBS” and “Reverse UBS” at a gradient of 48-56°C.  
Figure 4.23 PCR amplification of upstream putative ER binding site 
 
 
PCR of the upstream putative ER binding region using the primers “Forward UBS” and 
“Reverse UBS” did not result in any specific DNA product.  
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Primers to this region (Figure 4.16) were redesigned (F-560 and R+550) and the 
PCR was repeated using different combinations of forward and reverse primers (Figure 
4.24). PCR reactions B and C produced a visible DNA product. Since the expected size 
of the product is 1.7kb, the DNA sequence in reaction B is more than likely not the 
correct target sequence.  
Figure 4.24 PCR amplification of upstream putative ER binding region 
 
 
Four sets of PCR reactions (A-D) were set up using the primers: (A) Forward UBS-560 
and Reverse UBS+550 (B) Forward-UBS and Reverse UBS+550 (C) Forward UBS-560 
and Reverse-UBS (D) Forward-UBS and Reverse-UBS. The PCR reaction was run at a 
constant temperature of 52°C and PCR products were run on 1% agarose gel. The same 
reaction was set up with 1% DMSO, this achieved the same results as shown above.  
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As the primers in reaction (C) gave a specific DNA product of the expected size 
(1.7kb), these were used in subsequent experiments. A PCR reaction was set up using 
the primers “Forward UBS-560” and “Reverse-UBS” and run at a gradient of 50-60°C 
using gDNA as a template. 
Figure 4.25 UV visualization of agarose gel 
 
 
The PCR products were run on a 1% agarose gel with a 1kb molecular ladder. The DNA 
from the specific bands was cut from the gel and isolated using a DNA gel isolation kit.  
 
The isolated DNA which is referred to as UBS (upstream binding sequence) was Xho1 
digested for use in future ligation experiments.  
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4.5 Ligations 
The pGL4-26 vector (Promega) was used in all ligation experiments, this 
contains a minimal promoter, an Ampicillin resistance gene (β-lactamase) and a luc2 
(Luciferase) reporter gene. (Figure 4.26) 
Figure 4.26 Promega pGL4.26 plasmid with minimal promoter 
 
 
Sizes and locations of the specific plasmid components were obtained from the pGL4 
luciferase manual. The map was constructed using Bio-informatics software.  
 
The pGL4.26 plasmid and the full length (1.7kb) TGM2 regulatory sequence 
insert (Figure 4.19) were digested overnight with Xho1 restriction enzyme. pGL4.26 
was treated with Shrimp Alkaline Phosphatase (SAP) to remove 5‟ phosphates, 
preventing re-ligation of the plasmid. Both DNA strands were run on a 1% agarose gel 
to determine volumes required for ligation reaction. (Figure 4.27). 
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Figure 4.27 Xho1 digested pTGM2 and pGL4.26 
 
  
Digested pTGM2 and pGL4.26 were run on a 1% agarose gel with a 1kb molecular 
ladder. The intensity of the bands indicate their relative concentrations, which is used to 
determine the volumes required for the ligation reaction 
  
Multiple ligation reactions were set up with T4 DNA ligase (1.5µl), 10x ligase 
buffer (1.5µl), the insert (6µl) and varying volumes of plasmid (0.5µl to 2.0µl) to a final 
volume of 15µl. Also a vector-only ligation was set up as a negative control. The 
ligation mixtures were incubated at room temp for 1-2hrs prior to transforming in XL2 
ultra-competent cells (Stratagene) according to manufacturer‟s instructions. 
Transformed cells were plated on Ampicillin plates and incubated at 37°C overnight. 
All colonies (3) were re-cultured in 10mls of LB broth with added Ampicillin, while the 
vector-only control did not grow any colonies. Plasmid isolation was performed on the 
4 cultured broths to isolate the ligated plasmid. Each plasmid isolate was quantified, 
Xho1 digested, and run on 0.75% agarose gel.   
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Figure 4.28 UV visualisation of three isolated plasmids 
 
 
1µg of each isolated plasmid was run on 0.75% agarose gel. Sample number 3 has both 
the vector (5.8kb) and the insert (1.7kb) while both 1 and 2 have the plasmid only. 
 
The plasmid from sample number 3 was shown to contain the insert (referred to 
as pTGM2-luc in future experiments). The next step is to determine whether or not the 
insert is in the correct orientation. Two restriction enzyme digests were set up using 
HindIII and BglII as each of these enzymes cut both the insert and the vector in one 
position only. By analysing the size of the fragments, the orientation of the insert can be 
determined. Plasmid isolation using a Maxiprep kit was performed to isolate a large 
volume of the plasmid (pTGM2-luc). The isolated plasmid was quantified for use in 
transfection studies.   
Figure 4.29 Locations of HindIII and BglII cutting sites on TGM2-luc 
 
 
The diagram shows the pTGM2 insert, the multiple cloning site and the luciferase gene. 
As the distance between the two HindIII sites is 1.4kb and the total plasmid size is 
7.4kb, a HindIII digest will produce fragment sizes of 1.4 kb and 6 kb.  Also a BglII 
digest will produce fragment sizes of 7.2 kb and 200 bp. These exact fragment sizes are 
only formed when the pTGM2 sequence is inserted in the correct orientation.  
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Figure 4.30 HindIII and BglII restriction digest of isolated pTGM2-luc 
 
 
The isolated plasmid (pTGM2-luc) was digested with HindIII (Lane 1) and BglII (Lane 
2) in a single digest reaction. The fragments sizes from the HindIII digest were 6kb and 
1.4kb while the fragment sizes from the BglII digest were 7.2kb and 200bp. Therefore 
we can conclude the insert is in the correct orientation.   
 
The pTGM2-luc plasmid was then sequenced to confirm that the correct 
sequence from the TGM2 promoter region is incorporated into the plasmid (Figure 
4.31).  
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Figure 4.31 Chromatogram of sequenced pTGM2-luc plasmid 
 
This figure shows part of the chromatogram of sequenced pTGM2-luc viewed using 
Geospiza Finch TV 1.4. Highlighted in blue is the primer sequence used to amplify the 
TGM2 insert, indicating the start of the inserted sequence. Not shown is the putative 
ERE which is downstream of the sequenced region.  
 
The sequence data was aligned with the TGM2 sequence using the Bio-
informatics software CLC Main Workbench 5.0. Figure 4.32 shows a perfect alignment 
between the sequenced insert and the actual TGM2 target sequence.  
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Figure 4.32 Alignment between sequenced insert and expected sequence 
 
Figure shows comparison between sequenced insert (pTGM2-luc) and genomic 
sequence. Alignments were analysed using Bio-informatics software.  
 
 
We decided to focus on the cloned TGM2-luc plasmid and proceed with 
transfection studies using this plasmid to ascertain the transcriptional regulation of 
TGM2 by ER in presence and absence of E2/TAM.   
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4.6 Transfections 
At this point 1.7kb of the TGM2 promoter region has been cloned into a 
Luciferase plasmid. In order to study the regulation of TGM2 by ER with E2 or TAM, 
the pTGM2-luc plasmid (Figure 4.33) was transfected into HeLa cells.  
Figure 4.33 pGL4.26 luciferase vector with 1.7kb TGM2 insert 
 
 
Diagram of the constructed luciferase plasmid containing the luciferase gene, minimal 
promoter and TGM2 promoter insert, indicating sequenced region. 
 
Both ER positive and ER negative cancer cells were used in the transfection 
studies. In order to investigate the requirements of ER in the activation of TGM2, a 
transfection assay was set up using ER negative HeLa cells. In this assay a CMV-driven 
ERα plasmid was co-transfected with either pTGM2-luc, ERE-luciferase (3xERE-
TATA-luc) reporter (positive control) or the empty vector (pGL4.26) as a negative 
control. All cells in the transfection experiments are co-transfected with 100ng CMV-β-
gal (Figure 4.34). The β-galactosidase substrate Chlorophenol red-β-D-
galactopyranoside (CPRG) was added to the cell lysates and incubated at 37°C. The 
absorbance of each well was measured at 570nm, which was used to normalise the 
TGM2 insert 
β-lactamase (Amp R) 
Minimal Promoter 
Luc2 reporter gene 
Sequenced region 
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luciferase activity for transfection efficiency. The results of this transfection are 
presented in Figure 4.35. 
Figure 4.34 pCMV-β-gal plasmid used to normalise transfections 
 
Diagram of the β-gal plasmid with a β-lactamase gene and a β-galactosidase gene driven 
by a CMV promoter.  
 
Figure 4.35 Effects of E2 and ER on TGM2 activation 
 
HeLa cells were transfected with 2880ng plasmid (ERE-TATA, pGL4.26 or TGM2-
luc), 0 or 20ng ERα, along with 100ng CMV-βgal. Total DNA was 3μg/triplicate. After 
24hrs cells were treated with vehicle (V) or 10nM Estradiol (E2) with 1µM 4OHT or 
1µM ICI and then harvested and assayed for luciferase and β-gal activity. The effect of 
ERα on the activation of TGM2 was evaluated. Results are expressed as normalized 
luciferase activity (normalized with β-galactosidase for transfection efficiency) +/- 
standard deviation per triplicate sample of cells. Note: pGL4.26 transfection was not 
carried out for the E2/4OHT or E2/ICI treated cells. 
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From the graph we can see there is no significant activation of the TGM2 
plasmid (p=0.32). However there is significant activation of the positive control ERE-
TATA-luc by E2 (p<0.01) and repression of ERE-TATA-luc by 4OHT (p<0.01). This 
experiment was repeated a further 3 times in HeLa cells without any significant 
activation of pTGM2-luc. 
This experiment was repeated in both HeLa cells and Skbr-3 cells using the 
ligand ATRA (All-Trans Retinoic Acid), a known activator of TGM2 [89]. The results 
of this experiment are presented in Figure 4.36, which shows significant activation of 
the control plasmid ERE-TATA-luc by E2. However ATRA did not produce any 
significant activation of the TGM2 plasmid. One possible explanation for this is that as 
the location of the retinoid response element on TGM2 has not been fully established it 
may be further upstream than the sequence included in this plasmid.    
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Figure 4.36 Treatment of transfected cells with ATRA 
 
Skbr-3 cells were transfected with 2880ng plasmid (ERE-TATA, pGL4.26 or TGM2-
luc), 0 or 10ng ERα, along with 100ng CMV-βgal. Total DNA was 3μg/triplicate. After 
24hrs cells were treated with vehicle (V) or Oestradiol (E2) or ATRA and then 
harvested and assayed for luciferase and β-gal activity. The effect of ERα on the 
activation of TGM2 was evaluated. Results are expressed as normalized luciferase 
activity (normalized with β-galactosidase for transfection efficiency) +/- standard 
deviation per triplicate sample of cells and expressed as mean fold change over vehicle-
treated cells.  
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Oestrogen Receptor positive cells (MCF-7) were used in the following 
transfection experiment. ER positive cells were used here as previous experiments failed 
to show TGM2-luc activity. To out rule poor ER transfection efficiency as a cause of 
this, cells containing the ER are used. MCF-7 cells were transfected with the TGM2-
luc, ERE-TATA-luc and pGL4.26 plasmids. Following transfection cells were treated 
with the ER ligands, E2, TAM, and ICI (Figure 4.37). The aim of this experiment is to 
analyse the effects of ER ligands and the oestrogen receptor on the transcriptional 
activity of cloned TGM2-luc plasmid. 
Figure 4.37 Transfection of TGM2-luc in MCF-7 cells 
 
MCF-7 cells were transfected with 2900ng plasmid (ERE-TATA, pGL4.26 or TGM2-
luc) and 100ng CMV-βgal. Total DNA was 3μg/triplicate. After 24hrs cells were treated 
with vehicle (V), 10nM Oestradiol (E2), or 1uM All-Trans Retinoic Acid (ATRA) with 
1uM 4OHT or 1uM ICI, and then harvested and assayed for luciferase and β-gal 
activity. The effect of E2 or ATRA on the activation of TGM2 was evaluated. Results 
are expressed as normalized luciferase activity (normalized with β-galactosidase for 
transfection efficiency) +/- standard deviation per triplicate sample of cells. 
 
Although there is good activation of the ERE-TATA-luc with E2, there is no 
significant activation of the TGM2-luc plasmid (p>0.05). Also ERE-TATA-luc 
induction is inhibited by 4OHT, as shown here by a decrease in luciferase activity 
(p<0.01). This experiment was repeated giving the same results as shown here. The 
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putative ERE within the pTGM2-luc plasmid being tested may not be functional. This 
may explain the lack of luciferase activity in pTGM2-luc transfected cells.  
5 Discussion 
Tamoxifen (TAM) has been used clinically for more than 30 years to treat breast 
cancer, and for more than 10 years to reduce the risk of breast cancer in women at high 
risk of developing this disease. The activities of TAM and its metabolites 4-
Hydroxytamoxifen (4OHT) and Endoxifen, in breast cancer have primarily been 
attributed to their ability to inhibit ER signaling. Although clearly an ER antagonist in 
the breast, TAM has agonist activity in other ER target tissues and as such preserves 
bone mineral density but increases the risk for endometriosis and endometrial cancer, 
blood clots, and stroke.  However, it is not entirely clear how TAM, RAL, and other 
SERMs exhibit tissue-specific or promoter-specific activities through a single signaling 
pathway. This study aims to investigate the differential promoter-specific pharmacology 
of TAM in the context of breast cancer cells using the TGM2 gene as a model. 
The results of this study reveal the differential control of the TGM2 gene by the 
oestrogen receptor and TAM in the context of breast cancer cells. Figure 4.7 shows that 
ER/E2 induces expression of RET and TGM2 but co-treatment with TAM will inhibit 
RET but not TGM2. These results are interesting as we would expect all ER-regulated 
genes to be inhibited by TAM in breast cancer cells. Therefore TGM2 may be the first 
in a class of ER-regulated gene differentially regulated by TAM. 
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A further investigation into these findings leads us to examine the requirement 
of ER in the activation and inhibition of TGM2. An ER plasmid was transfected into ER 
negative cells breast cancer cells (MDA-231), using a β-gal plasmid as a control. ER-
transfected cells showed a significantly higher induction of TGM2 when treated with E2 
(p<0.01) over cells transfected with the β-gal plasmid (Figure 4.8). However although 
there was good activation of the WISP2 ER-regulated gene (control), there was only a 
slight but significant increase in TGM2 induction. One possible cause of this may be 
poor transfection efficiency, where an insufficient amount of ER required for TGM2 
activation was present in the cell.  
To explain the failure of TAM to inhibit ER-induced activation of TGM2 we 
investigated the hypothesis that activated AhR is preventing inhibition of this gene by a 
process of ER-AhR cross-talk. Figure 4.9 confirms that TAM is a potent activator of 
AhR, as shown by the large fold increase in CYP1A1 (AhR-responsive gene) induction. 
Figure 4.10 shows the effects of the AhR agonists, TAM and BNF on TGM2 mRNA 
expression. These results clearly show that activated AhR alone is not sufficient to 
maintain expression of TGM2. Although AhR is activated by TAM, it does not lead to 
transcription of TGM2 therefore we can out rule the involvement of AhR in TGM2 gene 
induction. 
Analysis of other related SERMs revealed that Endoxifen and 4OHT also show 
similar patterns to Tamoxifen in inhibiting ER mRNA induction of TGM2 while the 
SERM Raloxifene was very effective in inhibiting this induction. The fact that Endox 
and 4OHT both have similar patterns to TAM is not surprising given that they are 
structurally related to TAM.  
Although RAL functions in the same way as TAM, they have different patterns 
of activation and inhibition in different cells. RAL acts as an agonist in bone and an 
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antagonist in the uterus while TAM acts as an agonist in the bone and uterus (Table 
1.1). Our findings show that RAL and TAM have different inhibition patterns of the 
TGM2 gene in breast cancer cells. The prevailing question in this study is why two 
similar but distinct SERMs cause different activation patterns with the same gene in the 
same cells. While we know that upon E2 treatment, ER and other cofactors are recruited 
to gene regulatory regions to modulate gene expression, but depending on the promoter 
context and cellular background, TAM and E2 can regulate gene expression in a manner 
similar to or different from RAL/E2. It has been shown using phage-display/ELISA 
technology that the structures of the TAM-ER and RAL-ER complexes are not identical 
and show important differences that may contribute to differences in their patterns of 
gene regulation [26]. This would explain why RAL but not TAM can act as an 
antagonist in the uterus. It does not fully explain however why TAM has different 
patterns on the TGM2 gene in breast cancer cells while inhibiting all other ER-regulated 
genes. SERMs act in a promoter and cell-context specific manner. We hypothesise that 
TGM2 must have an oestrogen receptor responsive element in its regulatory region 
which is slightly different to that in other ER-regulated genes. Therefore binding of 
RAL/ER to TGM2 promoter would allow for the binding of co-repressors which inhibits 
gene transcription whereas binding of TAM-ER to the gene does not recruit co-
repressors, instead allowing for the recruitment of a co-activator complex leading to 
transcription.  
We set out to investigate the effects of TAM and its related compounds on the 
TGM2 gene expression in breast cancer cells. Our data highlights the differential 
pharmacology of TAM in the regulation of TGM2. However now the prevailing 
question is what makes TGM2 different from other ER-regulated genes. In order to 
accomplish a better understanding of TAM/ER action in breast cancer, TGM2 may be 
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used as a model gene which does not conform to the expected characteristics of an ER-
regulated gene. To investigate TGM2 further, we analysed the genomic sequence of its 
regulatory region.  
To understand the basis for the differential regulation of this gene we analysed 
2kbs of the sequence upstream of the TGM2 promoter. Two possible ER regulatory 
regions were located, one putative ERE (8 out of 10 match) and one AP-1 site (6 out of 
7 match) (Figure 1.13). These binding sites are a slight deviation from the canonical 
binding site. This slight difference in sequence may be a contributing factor to the 
differential pharmacology seen in these results. If the ER is indeed binding to these 
sequences we would not expect a typical binding site. ERα is known to activate AP-1 
controlled genes when bound by either E2 or TAM in the cytoplasm [90]. However our 
results show E2 is required for TGM2 up-regulation. This finding may out rule ER - 
AP-1 as a mode of TGM2 activation.  
Transfections were performed in MCF-7, HeLa and Skbr-3 cell types using the 
cloned TGM2-luc plasmid. Each experiment was designed to investigate specific 
requirements of TGM2 activation and inhibition. Our constructed plasmid did not show 
any significant luciferase activity in any of the experiments. As we have confirmed that 
the plasmid has the correct insert and orientation (Figure 4.31), these results may 
indicate that the ER is not actually binding to the sequence within the cloned 1.7kb 
TGM2 5‟ flanking region. However it is possible that the required coactivators or 
transcription factors are not present in sufficient quantity to induce transcription or 
perhaps other NRREs are required. As discussed earlier, two other proposed ER binding 
sites are present in the vicinity to the TGM2 gene, which was previously identified using 
chip-on-chip data shown in Figure 4.14 [35]. It is entirely possible that the ER is driving 
transcription of this gene through one of these putative binding sites as the ER can act at 
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a large distance from the promoter [91]. Further study is required to investigate the role 
of these putative ER binding sites in TGM2 regulation.  
Although other studies have examined TGM2 involvement in apoptosis, cell 
development and tumour migration and development, this is the first study on the 
hormonal regulation of TGM2 in the context of SERMs in breast cancer. Our findings 
indicate important differences in the regulation of TGM2 by E2 and SERMs that might 
impact on the activity of TGM2 in breast cancer cell migration and metastasis. 
In conclusion our data show the differential pharmacology of TGM2 in relation 
to TAM and Endoxifen. Cell culture experiments have demonstrated the role of ERα in 
TGM2 activation. We have identified two putative ER binding sites with the 5‟ flanking 
region, an ERE and an AP-1 site and cloned this region into a luciferase vector.  Finally 
our results suggest that the ER may not be binding to this region and instead my activate 
transcription from a more distal binding site. 
The continued mRNA expression of TGM2 in the presence of ER/TAM may 
have clinical significance due to its role in tumour suppression and prevention of 
metastasis, as discussed earlier. Further research is required to determine the role of 
TGM2 in tumour cells. 
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7 Appendix 
 
Table 7.1 UV quantification of isolated RNA (Raw data) 
Sample 
ID 
Net Abs 
260.0nm 
Net Abs 
280.0nm 260.0/280.0 
Dil 
Factor 
Conc. 
µg/ml 
1 0.1668 0.0744 2.2419 25.000 166.8 
2 0.1396 0.0613 2.2773 25.000 139.6 
3 0.1905 0.0847 2.2491 25.000 190.5 
4 0.1285 0.0557 2.3070 25.000 128.5 
5 0.1220 0.0553 2.2061 25.000 122.0 
6 0.1248 0.0548 2.2774 25.000 124.8 
7 0.1359 0.0594 2.2879 25.000 135.9 
8 0.1434 0.0625 2.2944 25.000 143.4 
9 0.1316 0.0579 2.2729 25.000 131.6 
10 0.1547 0.0672 2.3021 25.000 154.7 
11 0.1425 0.0627 2.2727 25.000 142.5 
12 0.1328 0.0601 2.2097 25.000 132.8 
13 0.1718 0.0753 2.2815 25.000 171.8 
14 0.1620 0.0732 2.2131 25.000 162.0 
15 0.1639 0.0728 2.2514 25.000 163.9 
RNA samples were diluted 1/25 in TE buffer prior to quantification. All RNA samples 
in these studies have a 260:280nm ratio of between 2.0 – 2.5 
 
Table 7.2 Volumes required for iScript RT-PCR reaction 
sample treatment Time µg/ml RNA µl/1µg 
RNA 
µl H20 
1 control - 166 6 9 
2 10nM E2 1hr 139 7.2 7.8 
3 
 
2hr 190 5.3 9.7 
4 
 
4hr 128 7.8 7.2 
5 
 
6hr 112 8.9 6.1 
6 100nM 40HT 1hr 124 8.1 6.9 
7 
 
2hr 135 7.4 7.6 
8 
 
4hr 143 7 8 
9 
 
6hr 131 7.6 7.4 
10 100nM BNF 1hr 154 6.5 8.5 
11 
 
2hr 142 7 8 
12 
 
4hr 132 7.6 7.4 
13 
 
6hr 171 5.8 9.2 
14 E2 + 4OHT 6hr 162 6.2 8.8 
15 E2 + BNF 6hr 163 6.1 8.9 
 
 
 
